| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2024 |
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, et al. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF8. PMID 38433347 DOI: 10.1158/1078-0432.CCR-23-0633 |
0.01 |
|
| 2024 |
Stauffer JA, Hyman D, Porrazzo G, Tice M, Li Z, Almerey T. A propensity score-matched analysis of laparoscopic versus open pancreaticoduodenectomy: Is there value to a laparoscopic approach? Surgery. PMID 38307785 DOI: 10.1016/j.surg.2023.12.021 |
0.01 |
|
| 2024 |
Hyman DA, Letchuman S, Bai G. Health Insurance Coverage-Is Broader Always Better? Jama Internal Medicine. PMID 38252444 DOI: 10.1001/jamainternmed.2023.7112 |
0.01 |
|
| 2023 |
Mattingly TJ, Hyman DA, Bai G. Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy. Jama Health Forum. 4: e233804. PMID 37921745 DOI: 10.1001/jamahealthforum.2023.3804 |
0.01 |
|
| 2023 |
Bai G, Letchuman S, Hyman DA. Do Nonprofit Hospitals Deserve Their Tax Exemption? The New England Journal of Medicine. 389: 196-197. PMID 37458238 DOI: 10.1056/NEJMp2303245 |
0.01 |
|
| 2023 |
Hyman DA, Lerner J, Magid DJ, Black B. Association of Past and Future Paid Medical Malpractice Claims. Jama Health Forum. 4: e225436. PMID 36763369 DOI: 10.1001/jamahealthforum.2022.5436 |
0.01 |
|
| 2023 |
Blake C, Almerey T, Hyman D, Nguyen J, Stauffer JA. Pancreaticoduodenectomy After Liver Transplantation: A Single-Center Experience. World Journal of Surgery. PMID 36637476 DOI: 10.1007/s00268-022-06887-1 |
0.01 |
|
| 2022 |
Hyman DW, Brennan ER, Spaulding AC, Colibaseanu DT, Akram Hussain MW, Muraleedharan D, Casler JD, Schreier DJ, Thompson KM, Edwards MA. The Impact of Caprini Guideline Indicated Venous Thromboembolism Prophylaxis in Colorectal Surgery Patients: Experience of a Single Health System. The American Surgeon. 31348221129514. PMID 36192381 DOI: 10.1177/00031348221129514 |
0.01 |
|
| 2022 |
Liu J, Hyman DA. Criminal Records and Licensure in Five Allied Health Professions: Is There Evidence of a Disparate Impact on Historically Marginalized Groups? Journal of Health Politics, Policy and Law. PMID 36174238 DOI: 10.1215/03616878-10234198 |
0.01 |
|
| 2022 |
Hyman DW, Almerey T, Mujkanovic A, Hammons I, Tice M, Stauffer JA. Comparing Post-Operative Outcomes of Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: Neoadjuvant Therapy versus Surgery First Approach. The American Surgeon. 31348221087900. PMID 35465681 DOI: 10.1177/00031348221087900 |
0.01 |
|
| 2022 |
Shrestha Bhattarai T, Shamu T, Gorelick AN, Chang MT, Chakravarty D, Gavrila EI, Donoghue MTA, Gao J, Patel S, Gao SP, Reynolds MH, Phillips SM, Soumerai T, Abida W, Hyman DM, et al. AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications. 13: 2111. PMID 35440569 DOI: 10.1038/s41467-022-29638-1 |
0.01 |
|
| 2022 |
Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, Friedman ND, de Bruijn I, Sumer O, Bielski CM, Savin C, Bourque C, Falcon C, Clarke N, Jing X, ... ... Hyman DM, et al. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications. 13: 1936. PMID 35383193 DOI: 10.1038/s41467-022-29700-y |
0.01 |
|
| 2022 |
Rosen EY, Won HH, Zheng Y, Cocco E, Selcuklu D, Gong Y, Friedman ND, de Bruijn I, Sumer O, Bielski CM, Savin C, Bourque C, Falcon C, Clarke N, Jing X, ... ... Hyman DM, et al. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications. 13: 1450. PMID 35304457 DOI: 10.1038/s41467-022-28848-x |
0.01 |
|
| 2022 |
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, ... ... Hyman DM, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. The New England Journal of Medicine. 386: 735-743. PMID 35196427 DOI: 10.1056/NEJMoa2114110 |
0.01 |
|
| 2022 |
LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto EM, Andre F, Smyth LM, Dogan S, Yu C, Wathoo C, et al. Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35190802 DOI: 10.1158/1078-0432.CCR-21-0885 |
0.01 |
|
| 2022 |
Bai G, Zare H, Hyman DA. Evaluation of Unreimbursed Medicaid Costs Among Nonprofit and For-Profit US Hospitals. Jama Network Open. 5: e2148232. PMID 35157060 DOI: 10.1001/jamanetworkopen.2021.48232 |
0.01 |
|
| 2021 |
Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, ... ... Hyman DM, et al. The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics. 53: 1577-1585. PMID 34741162 DOI: 10.1038/s41588-021-00949-1 |
0.01 |
|
| 2021 |
Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, Schoenthaler A, Houston Miller N, Hyman DJ. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension (Dallas, Tex. : 1979). HYP0000000000000203. PMID 34615363 DOI: 10.1161/HYP.0000000000000203 |
0.01 |
|
| 2021 |
Feldman RC, Hyman DA, Price WN, Ratain MJ. Negative innovation: when patents are bad for patients. Nature Biotechnology. 39: 914-916. PMID 34376839 DOI: 10.1038/s41587-021-00999-0 |
0.01 |
|
| 2021 |
Smyth LM, Reichel JB, Tang J, Patel JAA, Meng F, Selcuklu DS, Houck-Loomis B, You D, Samoila A, Schiavon G, Li BT, Razavi P, Piscuoglio S, Reis-Filho JS, Taylor BS, ... ... Hyman DM, et al. Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. Jco Precision Oncology. 5. PMID 34250397 DOI: 10.1200/PO.20.00184 |
0.01 |
|
| 2021 |
Tabernero J, Hyman DM, Soria JC. José "Pepe" Baselga, MD, PhD: In Memoriam (1959-2021). Cancer Discovery. PMID 33883166 DOI: 10.1158/2159-8290.CD-21-0458 |
0.01 |
|
| 2021 |
Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, et al. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Current Problems in Cancer. 100734. PMID 33865615 DOI: 10.1016/j.currproblcancer.2021.100734 |
0.01 |
|
| 2021 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, ... ... Hyman DM, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer. 7: 44. PMID 33863913 DOI: 10.1038/s41523-021-00251-7 |
0.01 |
|
| 2021 |
Hyman DM, Soria JC, Tabernero J. Building Bridges Between Drug Development and Cancer Science: A Tribute to José Baselga's Legacy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 33838220 DOI: 10.1016/j.annonc.2021.03.209 |
0.01 |
|
| 2021 |
Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus K, Sholl LM, Tsuji J, Hyman DM, Sisk AE, Shapiro GI, Vargas HA, et al. Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33727259 DOI: 10.1158/1078-0432.CCR-20-4548 |
0.01 |
|
| 2021 |
Kundra R, Zhang H, Sheridan R, Sirintrapun SJ, Wang A, Ochoa A, Wilson M, Gross B, Sun Y, Madupuri R, Satravada BA, Reales D, Vakiani E, Al-Ahmadie HA, Dogan A, ... ... Hyman D, et al. OncoTree: A Cancer Classification System for Precision Oncology. Jco Clinical Cancer Informatics. 5: 221-230. PMID 33625877 DOI: 10.1200/CCI.20.00108 |
0.01 |
|
| 2021 |
Wu J, Liu D, Offin M, Lezcano C, Torrisi JM, Brownstein S, Hyman DM, Gounder MM, Abida W, Drilon A, Harding JJ, Sullivan RJ, Janku F, Welsch D, Varterasian M, et al. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Investigational New Drugs. PMID 33389388 DOI: 10.1007/s10637-020-01035-9 |
0.01 |
|
| 2021 |
Pant S, Tabernero J, Massard C, Hyman D, Witt O, Doi T, Qin S, Lu-Emerson C, Hargrave D, Garcia-Corbacho J, Little S, Tolbert J, Santiago-Walker A, Moy C, Hammond C, et al. P86.03 A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations Journal of Thoracic Oncology. 16: S673. DOI: 10.1016/J.JTHO.2021.01.1232 |
0.01 |
|
| 2020 |
Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Discovery through clinical sequencing in oncology. Nature Cancer. 1: 774-783. PMID 35122052 DOI: 10.1038/s43018-020-0100-0 |
0.01 |
|
| 2020 |
Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, ... Hyman DM, et al. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers. 12. PMID 33158040 DOI: 10.3390/cancers12113246 |
0.01 |
|
| 2020 |
Jhaveri K, Chang MT, Juric D, Saura C, Gambardella V, Melnyk A, Patel MR, Ribrag V, Ma CX, Aljumaily R, Bedard PL, Sachdev JC, Dunn L, Won HH, Bond J, ... ... Hyman DM, et al. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with -Mutant Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33148674 DOI: 10.1158/1078-0432.CCR-20-2657 |
0.01 |
|
| 2020 |
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, ... ... Hyman DM, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics. PMID 33106634 DOI: 10.1038/s41588-020-00710-0 |
0.01 |
|
| 2020 |
Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, ... ... Hyman DM, et al. TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. Cancer Discovery. PMID 33004339 DOI: 10.1158/2159-8290.CD-20-0571 |
0.01 |
|
| 2020 |
Selenica P, Conlon N, Gonzalez C, Frosina D, Jungbluth AA, Beets-Tan RGH, Rao MK, Zhang Y, Benayed R, Ladanyi M, Solit DB, Chiang S, Hyman DM, Hensley ML, Soslow RA, et al. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. The American Journal of Surgical Pathology. PMID 32889887 DOI: 10.1097/PAS.0000000000001572 |
0.01 |
|
| 2020 |
Mondaca SP, Liu D, Flynn JR, Badson S, Hamaway S, Gounder MM, Khalil DN, Drilon AE, Li BT, Jhaveri KL, Schram AM, Kargus KE, Kasler MK, Blauvelt NM, Segal NH, ... ... Hyman DM, et al. Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. PMID 32809222 DOI: 10.1002/Cncr.33153 |
0.01 |
|
| 2020 |
Goldstein DA, Strohbehn GW, Serritella AV, Hyman DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass.). 26: 330-334. PMID 32732676 DOI: 10.1097/PPO.0000000000000461 |
0.01 |
|
| 2020 |
Hyman DA, Silver C. Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System. Cancer Journal (Sudbury, Mass.). 26: 298-303. PMID 32732672 DOI: 10.1097/PPO.0000000000000457 |
0.01 |
|
| 2020 |
Oaknin A, Friedman CF, Roman LD, D'Souza A, Brana I, Clement-Bidard F, Goldman J, Alvarez EA, Boni V, ElNaggar AC, Passalacqua R, Do KTM, Santin AD, Keyvanjah K, Xu F, ... ... Hyman DM, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology. PMID 32723675 DOI: 10.1016/j.ygyno.2020.07.025 |
0.01 |
|
| 2020 |
Vaughan EM, Hyman DJ, Naik AD, Samson SL, Razjouyan J, Foreyt JP. A Telehealth-supported, Integrated care with CHWs, and MEdication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial. Journal of General Internal Medicine. PMID 32700217 DOI: 10.1007/s11606-020-06017-4 |
0.01 |
|
| 2020 |
Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. Radiology. 192828. PMID 32515679 DOI: 10.1148/Radiol.2020192828 |
0.01 |
|
| 2020 |
Francis JH, Diamond EL, Chi P, Jaben K, Hyman DM, Abramson DH. MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocular Oncology and Pathology. 6: 159-163. PMID 32509759 DOI: 10.1159/000501155 |
0.01 |
|
| 2020 |
Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32348852 DOI: 10.1016/J.Annonc.2020.04.008 |
0.01 |
|
| 2020 |
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, ... ... Hyman DM, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With -Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32312891 DOI: 10.1158/1078-0432.CCR-19-3953 |
0.01 |
|
| 2020 |
Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM. Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32299819 DOI: 10.1158/1078-0432.CCR-19-3959 |
0.01 |
|
| 2020 |
Murciano-Goroff YR, Taylor BS, Hyman DM, Schram AM. Toward a More Precise Future for Oncology. Cancer Cell. 37: 431-442. PMID 32289268 DOI: 10.1016/j.ccell.2020.03.014 |
0.01 |
|
| 2020 |
Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet (London, England). 395: 1078-1088. PMID 32222192 DOI: 10.1016/S0140-6736(20)30164-1 |
0.01 |
|
| 2020 |
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, ... ... Hyman DM, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discovery. PMID 32213539 DOI: 10.1158/2159-8290.Cd-20-0215 |
0.01 |
|
| 2020 |
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Geoerger B, Dowlati A, Pappo AS, Bielack S, ... ... Hyman DM, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology. PMID 32105622 DOI: 10.1016/S1470-2045(19)30856-3 |
0.01 |
|
| 2020 |
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, ... Hyman DM, et al. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery. PMID 32029534 DOI: 10.1158/2159-8290.CD-19-1265 |
0.01 |
|
| 2020 |
Vaughan EM, Rueda JJ, Samson SL, Hyman DJ. Reducing the burden of diabetes treatment: A review of low-cost oral hypoglycemic medications. Current Diabetes Reviews. PMID 32026779 DOI: 10.2174/1573399816666200206112318 |
0.01 |
|
| 2020 |
Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Yabe M, Petrova-Drus K, Panageas KS, Reiner A, Rosenblum M, Diamond EL. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro-Oncology. PMID 31950179 DOI: 10.1093/neuonc/noaa008 |
0.01 |
|
| 2020 |
Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, ... ... Hyman DM, et al. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discovery. PMID 31924700 DOI: 10.1158/2159-8290.Cd-19-1209 |
0.01 |
|
| 2020 |
van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLoughlin KC, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 31898094 DOI: 10.1245/S10434-019-08107-Y |
0.01 |
|
| 2020 |
Berlin J, Hong DS, Deeken JF, Boni V, Oh D, Patel JD, Nanda S, Brega N, Childs BH, Hyman DM, Drilon AE. Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. Journal of Clinical Oncology. 38: 824-824. DOI: 10.1200/jco.2020.38.4_suppl.824 |
0.01 |
|
| 2020 |
Cleary JM, Iyer G, Oh D, Mellinghoff IK, Goyal L, Ng MC, Meric-Bernstam F, Matos I, Chao T, Ait Sarkouh R, Cretegny K, Nicolas-Metral V, Pokorska-Bocci A, Vaslin A, Zanna C, ... ... Hyman DM, et al. Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. Journal of Clinical Oncology. 38: 3603-3603. DOI: 10.1200/jco.2020.38.15_suppl.3603 |
0.01 |
|
| 2020 |
Bolton KL, Moukarzel LA, Ptashkin R, Gao T, Patel M, Caltabellotta N, Braunstein LZ, Aghajanian C, Hyman DM, Berger MF, Diaz LA, Li BT, Abida W, Schram AM, Weigelt B, et al. The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis. Journal of Clinical Oncology. 38: 1513-1513. DOI: 10.1200/jco.2020.38.15_suppl.1513 |
0.01 |
|
| 2020 |
Murciano-Goroff YR, Lebow ES, Tu H, Li M, Lim LP, Arbour KC, Travis W, Solit DB, Ladanyi M, Jones DR, Rudin CM, Martinez A, Myers ML, Makhnin A, Razavi P, ... ... Hyman DM, et al. Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer Clinical Cancer Research. 26: 12-12. DOI: 10.1158/1557-3265.Advprecmed20-12 |
0.01 |
|
| 2020 |
Reynolds T, Jack K, Kemeny M, Bulone L, Gonsky J, Kampel LJ, Hyman D, Solit DB, Conklin C, McMillan S, DeSimone N, Galle J, Naupari S, Brown CL. Abstract A090: Community partnerships expand access to tumor molecular profiling Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-A090 |
0.01 |
|
| 2020 |
Wildiers H, Boni V, Saura C, Oliveira M, Jhaveri K, Won H, Bidard F, Brufsky AM, Burkard ME, Cervantes A, Fernández-Martos C, Haley B, Loi S, Spanggaard I, Panni S, ... ... Hyman DM, et al. Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-08 |
0.01 |
|
| 2020 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Schram A, Varga A, Wong A, Ambrose H, Barnicle A, Carr TH, Bruin ECd, Salinas-Souza C, Foxley A, ... ... Hyman DM, et al. Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-05 |
0.01 |
|
| 2020 |
Murciano-Goroff YR, Arbour KC, Offin MD, Tu HY, Lebow ES, Shaffer TS, Bertucci C, Hosseini SA, Garg K, Lim LP, Li M, Chang JC, Reis-Filho JS, Razavi P, Isbell JM, ... ... Hyman DM, et al. Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers Clinical Trials. DOI: 10.1158/1538-7445.Am2020-709 |
0.01 |
|
| 2020 |
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Patel M, Berthon A, Syed A, Yabe M, Coombs C, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Lee C, ... ... Hyman D, et al. Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5703 |
0.01 |
|
| 2020 |
Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, ... ... Hyman DM, et al. Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors Cancer Research. 80: 5680-5680. DOI: 10.1158/1538-7445.Am2020-5680 |
0.01 |
|
| 2020 |
Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Discovery through clinical sequencing in oncology Nature Cancer. 1: 774-783. DOI: 10.1038/s43018-020-0100-0 |
0.01 |
|
| 2020 |
Dessources K, Holland A, Liu J, Lee S, Selenica P, Wu M, Stylianou A, Reis-Filho J, Hyman D, Hollmann T, Zamarin D, Weigelt B. Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type Gynecologic Oncology. 159: 116. DOI: 10.1016/j.ygyno.2020.05.132 |
0.01 |
|
| 2020 |
Farago A, Kummar S, Moreno V, Patel J, Lassen U, Rosen L, Childs B, Hyman D, Drilon A. B04 Activity of Larotrectinib in Tropomyosin Receptor Kinase Fusion Lung Cancer Journal of Thoracic Oncology. 15: S28. DOI: 10.1016/j.jtho.2019.12.073 |
0.01 |
|
| 2020 |
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, Sharon E, Gray R, Li S, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Conley B, et al. 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J Annals of Oncology. 31: S479-S480. DOI: 10.1016/j.annonc.2020.08.667 |
0.01 |
|
| 2019 |
Hyman DM, Tran B, Paz-Ares L, Machiels JP, Schellens JH, Bedard PL, Campone M, Cassier PA, Sarantopoulos J, Vaishampayan U, Chugh R, Mahipal A, Lockhart AC, Sessa C, Zander T, et al. Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. Jco Precision Oncology. 3: 1-13. PMID 35100734 DOI: 10.1200/PO.19.00221 |
0.01 |
|
| 2019 |
Subbiah V, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gonçalves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, ... ... Hyman DM, et al. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. Jco Precision Oncology. 3. PMID 32914022 DOI: 10.1200/PO.18.00266 |
0.01 |
|
| 2019 |
Tao JJ, Eubank MH, Schram AM, Cangemi N, Pamer E, Rosen EY, Schultz N, Chakravarty D, Philip J, Hechtman JF, Harding JJ, Smyth LM, Jhaveri KL, Drilon A, Ladanyi M, ... ... Hyman DM, et al. Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. Jco Precision Oncology. 3. PMID 32914018 DOI: 10.1200/PO.19.00066 |
0.01 |
|
| 2019 |
Carlo MI, Khan N, Zehir A, Patil S, Ged Y, Redzematovic A, Coskey DT, Hyman DM, Ladanyi M, Chen YB, Robson M, Hakimi AA, Lee CH, Feldman DR, Gao J, et al. Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. Jco Precision Oncology. 3. PMID 32914011 DOI: 10.1200/PO.18.00372 |
0.01 |
|
| 2019 |
Rosen EY, Schram AM, Young RJ, Schreyer MW, Hechtman JF, Shu CA, Ku NC, Hyman DM, Drilon A. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors. Jco Precision Oncology. 3. PMID 32914009 DOI: 10.1200/PO.19.00009 |
0.01 |
|
| 2019 |
Cadoo KA, Mandelker DL, Mukherjee S, Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel Y, Arnold AG, Sheehan M, Pradhan N, Joseph V, Chi DS, Gardner GJ, ... ... Hyman D, et al. Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. Jco Precision Oncology. 3. PMID 32775946 DOI: 10.1200/po.18.00338 |
0.01 |
|
| 2019 |
Hyman DM, Ladanyi M. Foreword. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: viii1-viii2. PMID 32223933 DOI: 10.1093/annonc/mdz409 |
0.01 |
|
| 2019 |
Matos I, Goyal L, Cleary J, Voss M, Oh D, Bernstam FM, Ng C, Iyer G, Ishii N, Hu Y, Chessex AV, Pokorska-Bocci A, Nicolas V, Kirpicheva Y, Zanna C, ... ... Hyman D, et al. Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv122-iv123. PMID 32085006 DOI: 10.1093/annonc/mdz157.002 |
0.01 |
|
| 2019 |
Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. PMID 31880826 DOI: 10.1002/cncr.32677 |
0.01 |
|
| 2019 |
Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, Shifman S, Gong Y, Kundra R, Solomon JP, Bardelli A, Scaltriti M, Drilon A, Iasonos A, Taylor BS, ... Hyman DM, et al. TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31871300 DOI: 10.1158/1078-0432.CCR-19-3165 |
0.01 |
|
| 2019 |
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, ... ... Hyman DM, et al. Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. Nature. PMID 31822847 DOI: 10.1038/s41586-019-1839-2 |
0.01 |
|
| 2019 |
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sorensen M, ... ... Hyman DM, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery. PMID 31806627 DOI: 10.1158/2159-8290.Cd-19-0966 |
0.01 |
|
| 2019 |
Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, Venn O, Lim R, Anand A, Maddala T, Gnerre S, ... ... Hyman DM, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine. PMID 31768066 DOI: 10.1038/S41591-019-0652-7 |
0.01 |
|
| 2019 |
Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, ... ... Hyman DM, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine. PMID 31768065 DOI: 10.1038/S41591-019-0653-6 |
0.01 |
|
| 2019 |
Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecologic Oncology. PMID 31757464 DOI: 10.1016/j.ygyno.2019.10.028 |
0.01 |
|
| 2019 |
Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, ... ... Hyman DM, et al. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Jama Oncology. PMID 31725847 DOI: 10.1001/Jamaoncol.2019.3985 |
0.01 |
|
| 2019 |
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 575: 299-309. PMID 31723286 DOI: 10.1038/s41586-019-1730-1 |
0.01 |
|
| 2019 |
Ulaner GA, Saura C, Piha-Paul SA, Mayer IA, Quinn DI, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. Impact of FDG PET Imaging for Expanding Patient Eligibility & Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548342 DOI: 10.1158/1078-0432.Ccr-19-1658 |
0.01 |
|
| 2019 |
Hyman DA, Silver C. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It? The Journal of Legal Medicine. 39: 137-149. PMID 31503533 DOI: 10.1080/01947648.2019.1645542 |
0.01 |
|
| 2019 |
Guo R, Schreyer M, Chang JC, Rothenberg SM, Henry D, Cotzia P, Kris MG, Rekhtman N, Young RJ, Hyman DM, Drilon A. Response to Selective RET Inhibition With LOXO-292 in a Patient With Fusion-Positive Lung Cancer With Leptomeningeal Metastases. Jco Precision Oncology. 3. PMID 31485557 DOI: 10.1200/PO.19.00021 |
0.01 |
|
| 2019 |
Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, ... ... Hyman DM, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. PMID 31406350 DOI: 10.1038/S41591-019-0542-Z |
0.01 |
|
| 2019 |
Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31375766 DOI: 10.1038/s41379-019-0324-7 |
0.01 |
|
| 2019 |
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, ... ... Hyman DM, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. PMID 31292550 DOI: 10.1038/s41586-019-1382-1 |
0.01 |
|
| 2019 |
Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31263031 DOI: 10.1158/1078-0432.Ccr-19-0032 |
0.01 |
|
| 2019 |
George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, et al. Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews. 76: 33-40. PMID 31108240 DOI: 10.1016/J.Ctrv.2019.04.004 |
0.01 |
|
| 2019 |
Tao JJ, Cangemi NA, Makker V, Cadoo K, Liu JF, Rasco DW, Navarro WH, Haqq CM, Hyman DM. First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31068369 DOI: 10.1158/1078-0432.CCR-19-1065 |
0.01 |
|
| 2019 |
Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, Ptashkin RN, Won H, Chang J, Halpenny DF, Schram AM, Rudin CM, Hyman DM, Arcila ME, Berger MF, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no driver alteration detected by DNA sequencing and low tumor mutation burden. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31028088 DOI: 10.1158/1078-0432.CCR-19-0225 |
0.01 |
|
| 2019 |
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology. PMID 30922731 DOI: 10.1016/S1470-2045(19)30020-8 |
0.01 |
|
| 2019 |
Diamond EL, Reiner AS, Buthorn JJ, Shuk E, Applebaum AJ, Hyman DM, Abdel-Wahab O, Rampal R, Janku F, Brewer K, Campbell J, Mao JJ, Atkinson TM, Panageas KS. A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood Advances. 3: 934-938. PMID 30917949 DOI: 10.1182/Bloodadvances.2018030502 |
0.01 |
|
| 2019 |
Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, ... ... Hyman DM, et al. Patient-driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-driven Cancer. Cancer Discovery. PMID 30877085 DOI: 10.1158/2159-8290.Cd-18-0953 |
0.01 |
|
| 2019 |
Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, ... ... Hyman DM, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. PMID 30867592 DOI: 10.1038/S41586-019-1012-Y |
0.01 |
|
| 2019 |
Vaughan EM, Naik AD, Lewis CM, Foreyt JP, Samson SL, Hyman DJ. Telemedicine Training and Support for Community Health Workers: Improving Knowledge of Diabetes. Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association. PMID 30839244 DOI: 10.1089/tmj.2018.0313 |
0.01 |
|
| 2019 |
Feit NZ, Goldman DA, Smith E, Deighan J, Iasonos A, Zivanovic O, Hyman DM. Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. Jama Oncology. PMID 30816938 DOI: 10.1001/jamaoncol.2018.7002 |
0.01 |
|
| 2019 |
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, et al. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. PMID 30755741 DOI: 10.1038/S41586-019-0974-0 |
0.01 |
|
| 2019 |
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. 9: 303. PMID 30737217 DOI: 10.1158/2159-8290.Cd-18-1515 |
0.01 |
|
| 2019 |
Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, et al. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30715161 DOI: 10.1093/annonc/mdz036 |
0.01 |
|
| 2019 |
Cocco E, Benhamida J, Middha S, Zehir A, Mullaney K, Shia J, Yaeger R, Zhang L, Wong D, Villafania L, Nafa K, Scaltriti M, Drilon A, Saltz L, Schram AM, ... ... Hyman DM, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Research. PMID 30643016 DOI: 10.1158/0008-5472.Can-18-3126 |
0.01 |
|
| 2019 |
Ng MCH, Goyal L, Bang Y, Oh D, Chao T, Cleary JM, Voss MH, Meric-Bernstam F, Iyer G, Heist RS, Ishii N, Kirpicheva Y, Pokorska-Bocci A, Vaslin A, Hu Y, ... ... Hyman D, et al. AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results Hepatobiliary Surgery and Nutrition. 8: AB065-AB065. DOI: 10.21037/HBSN.2019.AB065 |
0.01 |
|
| 2019 |
Hyman DM, Goyal L, Grivas P, Meric-Bernstam F, Tabernero J, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin A, Zanna C, Flaherty K. FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. Journal of Clinical Oncology. 37: TPS3157-TPS3157. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS3157 |
0.01 |
|
| 2019 |
Hyman DM, Zelnak AB, Bauer TM, Ulahannan SV, Ford JM, Cesari R, Hoyle M, Chappey C, Stewart R, Conte U, Yap TA. JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect. Journal of Clinical Oncology. 37: TPS2660-TPS2660. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS2660 |
0.01 |
|
| 2019 |
Agarwal R, Cangemi NA, Epstein AS, Harding JJ, Segal NH, Reidy DL, Hyman DM, Saltz LB. Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers. Journal of Clinical Oncology. 37: e15700-e15700. DOI: 10.1200/JCO.2019.37.15_SUPPL.E15700 |
0.01 |
|
| 2019 |
Cho BC, Drilon AE, Doebele RC, Kim D, Lin JJ, Lee J, Ahn M, Zhu VW, Ejadi S, Camidge DR, Liu YJ, Stopatschinskaja S, Cui JJ, Hyman DM, Ou SI, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). Journal of Clinical Oncology. 37: 9011-9011. DOI: 10.1200/JCO.2019.37.15_SUPPL.9011 |
0.01 |
|
| 2019 |
Li BT, Shen R, Offin M, Buonocore DJ, Myers ML, Venkatesh A, Razavi P, Ginsberg MS, Ulaner GA, Solit DB, Hyman DM, Rudin CM, Gedvilaite E, Tsui D, Arcila ME, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. Journal of Clinical Oncology. 37: 6001-6001. DOI: 10.1200/Jco.2019.37.15_Suppl.6001 |
0.01 |
|
| 2019 |
Varghese AM, Patel JAA, Janjigian YY, Meng F, Selcuklu SD, Zimel C, Hyman DM, Iyer G, Houck-Loomis B, Abou-Alfa GK, Berger MF, Lowery MA. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. Journal of Clinical Oncology. 37: 4096-4096. DOI: 10.1200/Jco.2019.37.15_Suppl.4096 |
0.01 |
|
| 2019 |
Schram AM, Benayed R, Somwar R, Rekhtman N, Arcila ME, Ladanyi M, Hyman DM, Drilon AE. Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study. Journal of Clinical Oncology. 37: 3129-3129. DOI: 10.1200/JCO.2019.37.15_SUPPL.3129 |
0.01 |
|
| 2019 |
Dunbar A, Bolton K, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, Wills JM, Kelly D, Farina M, Kishore S, Juluru K, Iyengar N, Hyman DM, Zehir A, Park W, et al. Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy Blood. 134: 633-633. DOI: 10.1182/Blood-2019-124242 |
0.01 |
|
| 2019 |
Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro GI, Lu J, Brufsky A, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler RE, ... ... Hyman DM, et al. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-929 |
0.01 |
|
| 2019 |
Srinivasan P, Bandlamudi C, Shia J, Latham AS, Jonsson P, Penson A, Middha S, Hechtman J, Zehir A, Richards A, Chawan S, Kemel Y, Mandelker D, Zhang L, Hyman D, et al. Abstract 4158: Dissecting the role of zygosity and lineage in Lynch Syndrome-associated microsatellite Instability Epidemiology. DOI: 10.1158/1538-7445.Sabcs18-4158 |
0.01 |
|
| 2019 |
Patel J, Hasan M, Meng F, Jing X, Tam G, Johnson I, Zheng Y, Bandlamudi C, Stewart C, Won H, Hampton O, Schram A, Rosen E, Drilon A, Varghese A, ... Hyman D, et al. Abstract 2516: A bioinformatics framework for high-sensitivity detection and monitoring of oncogenic gene fusions in plasma cfDNA Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2516 |
0.01 |
|
| 2019 |
Bolton K, Ptashkin R, Braunstein L, Gao T, Devlin SM, Kelly D, Coombs C, Patel M, Moarii M, Bernard E, Berthon A, Boucai L, Glodzik D, Martin A, Stadler Z, ... ... Hyman D, et al. Abstract LB-304: Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-304 |
0.01 |
|
| 2019 |
Cocco E, Kulick A, Misale S, Yaeger R, Razavi P, Won HH, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, ... ... Hyman DM, et al. Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-118 |
0.01 |
|
| 2019 |
Hyman D, Kummar S, Farago A, Geoerger B, Mau-Sorensen M, Taylor M, Garralda E, Nagasubramanian R, Natheson M, Song L, Capra M, Jorgensen M, Ho A, Shukla N, Smith S, et al. Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct127 |
0.01 |
|
| 2019 |
Schram A, Spreafico A, Oliva M, Brana I, Garralda E, Lakhani N, Hoff DV, Borazanci E, Pandya N, Hoffman K, Hallett R, Giblin P, Anido J, Kelly A, Wasserman R, ... ... Hyman DM, et al. Abstract CT014: Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct014 |
0.01 |
|
| 2019 |
Cadoo KA, Mandelker DL, Mukherjee S, Stewart C, DeLair D, Ravichandran V, Srinivasan P, Hurley D, Kemel Y, Arnold AG, Sheehan M, Pradhan N, Joseph V, Chi DS, Gardner GJ, ... ... Hyman DM, et al. Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer Obstetrical & Gynecological Survey. 74: 473-474. DOI: 10.1097/OGX.0000000000000706 |
0.01 |
|
| 2019 |
Doz F, Geoerger B, DuBois SG, Grilley-Olson JE, van Tilburg CM, Italiano A, Lissat A, Jin Kang H, Tahara M, Boni V, Perreault S, Capra M, Nanda S, Brega N, Holynskyj A, ... ... Hyman DM, et al. RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 21: vi231-vi231. DOI: 10.1093/neuonc/noz175.968 |
0.01 |
|
| 2019 |
Italiano A, Nanda S, Keating K, Childs B, Fellous M, Drilon A, Hyman D. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients Annals of Oncology. 30: v183-v184. DOI: 10.1093/annonc/mdz244.047 |
0.01 |
|
| 2019 |
Drilon A, Cho B, Kim D, Lee J, Lin J, Zhu V, Camidge R, Stopatschinskaja S, Cui J, Hyman D, Ou S, Shaw A, Doebele R. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study) Annals of Oncology. 30: v162. DOI: 10.1093/annonc/mdz244.006 |
0.01 |
|
| 2019 |
D’Souza A, Roman L, Saura C, Braña I, Shapiro G, Passalacqua R, Piha-Paul S, Cutler R, Shahin S, Eli L, Xu F, Dujka M, Lalani A, Bryce R, Meric-Bernstam F, ... ... Hyman D, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT ‘basket’ trial Gynecologic Oncology. 154: 11. DOI: 10.1016/J.YGYNO.2019.04.033 |
0.01 |
|
| 2019 |
Offin M, Pak T, Mondaca S, Montecalvo J, Rekhtman N, Halpenny D, Wu S, Kris M, Paik P, Riely G, Rudin C, Hyman D, Hellmann M, Drilon A, Land J, et al. P1.04-39 Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers Journal of Thoracic Oncology. 14: S455. DOI: 10.1016/J.Jtho.2019.08.942 |
0.01 |
|
| 2019 |
Farago A, Kummar S, Moreno V, Patel J, Lassen U, Rosen L, Ku N, Cox M, Nanda S, Childs B, Hyman D, Drilon A. MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer Journal of Thoracic Oncology. 14: S283-S284. DOI: 10.1016/j.jtho.2019.08.570 |
0.01 |
|
| 2018 |
Raje N, Chau I, Hyman DM, Ribrag V, Blay JY, Tabernero J, Elez E, Wolf J, Yee AJ, Kaiser M, Landau H, Michot JM, Hollebecque A, Veronese L, Makrutzki M, et al. Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. Jco Precision Oncology. 2. PMID 32913989 DOI: 10.1200/PO.18.00070 |
0.01 |
|
| 2018 |
Schram AM, Jonsson P, Drilon A, Bale TA, Hechtman JF, Benayed R, Hanusch B, Young RJ, Grommes C, Ku N, Kaley T, Hyman DM, Taylor BS. Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. Jco Precision Oncology. 2. PMID 31218270 DOI: 10.1200/PO.18.00089 |
0.01 |
|
| 2018 |
Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. The Journal of Molecular Diagnostics : Jmd. PMID 30576871 DOI: 10.1016/J.Jmoldx.2018.10.006 |
0.01 |
|
| 2018 |
Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, ... ... Hyman DM, et al. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature Medicine. PMID 30559419 DOI: 10.1038/S41591-018-0274-5 |
0.01 |
|
| 2018 |
Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, et al. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology. PMID 30470581 DOI: 10.1016/J.Ygyno.2018.11.025 |
0.01 |
|
| 2018 |
Schram AM, Gandhi L, Mita MM, Damstrup L, Campana F, Hidalgo M, Grande E, Hyman DM, Heist RS. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. British Journal of Cancer. PMID 30425349 DOI: 10.1038/s41416-018-0322-4 |
0.01 |
|
| 2018 |
Vaughan EM, Johnston CA, Arlinghaus KR, Hyman DJ, Foreyt JP. A Narrative Review of Diabetes Group Visits in Low-Income and Underserved Settings. Current Diabetes Reviews. PMID 30421682 DOI: 10.2174/1573399814666181112145910 |
0.01 |
|
| 2018 |
Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, et al. Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell. PMID 30393068 DOI: 10.1016/J.Ccell.2018.10.003 |
0.01 |
|
| 2018 |
Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, ... ... Hyman DM, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800283. PMID 30376427 DOI: 10.1200/Jco.18.00283 |
0.01 |
|
| 2018 |
Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, Shia J, Hechtman JF, Kundra R, El Dika I, Do RK, Sun Y, Kingham TP, D'Angelica MI, Berger MF, ... Hyman DM, et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30373752 DOI: 10.1158/1078-0432.CCR-18-2293 |
0.01 |
|
| 2018 |
Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discovery. PMID 30355724 DOI: 10.1158/2159-8290.Cd-18-0877 |
0.01 |
|
| 2018 |
Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, ... ... Hyman DM, et al. BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018789990. PMID 30351999 DOI: 10.1200/JCO.2018.78.9990 |
0.01 |
|
| 2018 |
Hyman DA. The Medicalization of Poverty: A Dose of Theory. The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics. 46: 582-587. PMID 30336086 DOI: 10.1177/1073110518804200 |
0.01 |
|
| 2018 |
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, ... ... Hyman DM, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 11. PMID 30301790 DOI: 10.1126/Scisignal.Aat9773 |
0.01 |
|
| 2018 |
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, ... ... Hyman DM, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 34: 427-438.e6. PMID 30205045 DOI: 10.1016/J.Ccell.2018.08.008 |
0.01 |
|
| 2018 |
Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP. Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood. PMID 30181173 DOI: 10.1182/blood-2018-07-859769 |
0.01 |
|
| 2018 |
Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, ... ... Hyman DM, et al. Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. Cancer Discovery. PMID 30093503 DOI: 10.1158/2159-8290.CD-18-0484 |
0.01 |
|
| 2018 |
Gottesdiener LS, O'Connor S, Busam KJ, Won H, Solit DB, Hyman DM, Shoushtari AN. Rates of Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an -amplified Acral Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30093446 DOI: 10.1158/1078-0432.CCR-18-1397 |
0.01 |
|
| 2018 |
Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo K, Grisham R, O'Cearbhaill RE, Tew W, Konner J, Hensley ML, Makker V, Sabbatini PJ, Spriggs DR, ... ... Hyman DM, et al. CLINICAL UTILITY OF PROSPECTIVE MOLECULAR CHARACTERIZATION IN ADVANCED ENDOMETRIAL CANCER. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30068706 DOI: 10.1158/1078-0432.Ccr-18-0412 |
0.01 |
|
| 2018 |
Cheng ML, Berger MF, Hyman DM, Solit DB. Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews. Cancer. PMID 30030494 DOI: 10.1038/s41568-018-0043-2 |
0.01 |
|
| 2018 |
Biswas C, Rao S, Slade K, Hyman D, Dersh D, Mantegazza AR, Zoltick PW, Marks MS, Argon Y, Behrens EM. Tyrosine 870 of TLR9 is critical for receptor maturation rather than phosphorylation-dependent ligand-induced signaling. Plos One. 13: e0200913. PMID 30024926 DOI: 10.1371/Journal.Pone.0200913 |
0.01 |
|
| 2018 |
Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, ... ... Hyman DM, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics. PMID 30013179 DOI: 10.1038/S41588-018-0165-1 |
0.01 |
|
| 2018 |
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, ... ... Hyman DM, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779777. PMID 29989854 DOI: 10.1200/Jco.2018.77.9777 |
0.01 |
|
| 2018 |
Carlo MI, Mukherjee S, Mandelker D, Vijai J, Kemel Y, Zhang L, Knezevic A, Patil S, Ceyhan-Birsoy O, Huang KC, Redzematovic A, Coskey DT, Stewart C, Pradhan N, Arnold AG, ... ... Hyman DM, et al. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. Jama Oncology. PMID 29978187 DOI: 10.1001/Jamaoncol.2018.1986 |
0.01 |
|
| 2018 |
Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, ... ... Hyman DM, et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of Clinical Investigation. PMID 29920189 DOI: 10.1172/Jci120787 |
0.01 |
|
| 2018 |
Ptashkin RN, Mandelker DL, Coombs CC, Bolton K, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Arcila ME, Ladanyi M, Zhang L, Levine RL, Berger MF, Zehir A. Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. Jama Oncology. PMID 29872864 DOI: 10.1001/jamaoncol.2018.2297 |
0.01 |
|
| 2018 |
Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, et al. Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." Urologic Oncology. PMID 29859727 DOI: 10.1016/j.urolonc.2018.05.011 |
0.01 |
|
| 2018 |
Tao JJ, Schram AM, Harding JJ, Drilon A, Hyman DM. Learning All That We Can From MyPathway. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018784728. PMID 29856696 DOI: 10.1200/JCO.2018.78.4728 |
0.01 |
|
| 2018 |
Lowery MA, Ptashkin RN, Jordan EJ, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, ... ... Hyman DM, et al. Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29848569 DOI: 10.1158/1078-0432.Ccr-18-0078 |
0.01 |
|
| 2018 |
Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, ... ... Hyman DM, et al. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer. PMID 29795308 DOI: 10.1038/s41416-018-0102-1 |
0.01 |
|
| 2018 |
LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE. A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 29757876 DOI: 10.1097/IGC.0000000000001280 |
0.01 |
|
| 2018 |
van Beek EJAH, Hernandez JM, Goldman DA, Davis JL, McLaughlin K, Ripley RT, Kim TS, Tang LH, Hechtman JF, Zheng J, Capanu M, Schultz N, Hyman DM, Ladanyi M, Berger MF, et al. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology. PMID 29725898 DOI: 10.1245/S10434-018-6502-X |
0.01 |
|
| 2018 |
Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, et al. Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation. Heart Failure. 11: e004408. PMID 29664405 DOI: 10.1161/Circheartfailure.117.004408 |
0.01 |
|
| 2018 |
Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe ER, Fink A, Wacheck V, Moore KN. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29636360 DOI: 10.1158/1078-0432.CCR-17-3421 |
0.01 |
|
| 2018 |
Xu A, Hyman D, Lu LB. Cefazolin-Related Acute Interstitial Nephritis with Associated Nephrotic-Range Proteinuria: A Case Report. Drug Safety - Case Reports. 5: 16. PMID 29633042 DOI: 10.1007/s40800-018-0080-5 |
0.01 |
|
| 2018 |
Hyman DM, Rizvi NA, Natale RB, Armstrong DK, Birrer MJ, Recht L, Dotan E, Makker V, Kaley TJ, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar MM. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined With Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29559563 DOI: 10.1158/1078-0432.Ccr-17-1775 |
0.01 |
|
| 2018 |
Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, et al. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American Journal of Surgical Pathology. PMID 29553955 DOI: 10.1097/PAS.0000000000001055 |
0.01 |
|
| 2018 |
Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, ... ... Hyman DM, et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute. PMID 29506128 DOI: 10.1093/Jnci/Djy024 |
0.01 |
|
| 2018 |
Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica. PMID 29472347 DOI: 10.3324/haematol.2017.185298 |
0.01 |
|
| 2018 |
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, ... ... Hyman DM, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England Journal of Medicine. 378: 731-739. PMID 29466156 DOI: 10.1056/Nejmoa1714448 |
0.01 |
|
| 2018 |
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 554: 189-194. PMID 29420467 DOI: 10.1038/Nature25475 |
0.01 |
|
| 2018 |
Ji Y, Jin JY, Hyman DM, Kim G, Suri A. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. Clinical and Translational Science. PMID 29392871 DOI: 10.1111/cts.12540 |
0.01 |
|
| 2018 |
Yaeger R, Chatila WK, Lipsyc MD, Hechtman JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A, Donoghue MTA, You D, Viale A, Kemeny N, Segal NH, Stadler ZK, ... ... Hyman DM, et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell. 33: 125-136.e3. PMID 29316426 DOI: 10.1016/J.Ccell.2017.12.004 |
0.01 |
|
| 2018 |
Hyman DM, Brana I, Spreafico A, Schram AM, Pandya NB, Hoffman K, Hallet R, Giblin P, Anido J, Ruano IH, Wasserman R, Magram J, Siu LL, Tabernero J, Seoane J, et al. A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors. Journal of Clinical Oncology. 36: TPS2602-TPS2602. DOI: 10.1200/JCO.2018.36.15_SUPPL.TPS2602 |
0.01 |
|
| 2018 |
Tao J, Eubank MH, Pamer E, Cangemi NA, Drilon AE, Harding JJ, Schram AM, Smyth LM, Jhaveri KL, Li BT, Chakravarty D, Zehir A, Berger MF, Schultz N, Pinkhasik A, ... ... Hyman DM, et al. PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials. Journal of Clinical Oncology. 36: 6507-6507. DOI: 10.1200/JCO.2018.36.15_suppl.6507 |
0.01 |
|
| 2018 |
Friedman CF, Donoghue M, Vivek M, Aghajanian C, Abu-Rustum N, Cadoo KA, Grisham RN, Hensley ML, Konner JA, Kyi C, Leitao MM, Makker V, O'Cearbhaill RE, Tew WP, Weigelt B, ... ... Hyman DM, et al. The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer. Journal of Clinical Oncology. 36: 5531-5531. DOI: 10.1200/Jco.2018.36.15_Suppl.5531 |
0.01 |
|
| 2018 |
Fernandes GDS, Chatila WK, Yaeger R, Mendelsohn RB, Stadler ZK, Segal NH, Varghese AM, Lagunes DR, Diaz LA, Shia J, Vakiani E, Hechtman JF, Schultz N, Berger MF, Hyman DM, et al. Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC). Journal of Clinical Oncology. 36: 3520-3520. DOI: 10.1200/JCO.2018.36.15_SUPPL.3520 |
0.01 |
|
| 2018 |
Drilon AE, Ou SI, Cho BC, Kim D, Lee J, Lin JJ, Zhu VW, Kim H, Kim TM, Ahn M, Camidge DR, Lim JK, Stopatschinskaja S, Cui JJ, Hyman DM, et al. A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). Journal of Clinical Oncology. 36: 2513-2513. DOI: 10.1200/JCO.2018.36.15_SUPPL.2513 |
0.01 |
|
| 2018 |
Li BT, Makker V, Buonocore DJ, Offin MD, Olah ZT, Panora E, Shen R, Ho AL, Yaeger R, Iyer G, Ginsberg MS, Ulaner G, Solit DB, Hyman DM, Rudin CM, et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. Journal of Clinical Oncology. 36: 2502-2502. DOI: 10.1200/JCO.2018.36.15_SUPPL.2502 |
0.01 |
|
| 2018 |
Cercek A, Kemel Y, Mandelker D, Stewart C, Arnold AG, Sheehan M, Yaeger R, Segal NH, Varghese AM, Saltz LB, Diaz LA, Shia J, Hyman DM, Berger MF, Solit DB, et al. Prevalence of germline genetic alterations in colorectal cancer patients. Journal of Clinical Oncology. 36: 1577-1577. DOI: 10.1200/JCO.2018.36.15_SUPPL.1577 |
0.01 |
|
| 2018 |
Benayed R, Offin MD, Mullaney KA, Sukhadia P, Rios KM, Desmeules P, Chang JC, Hyman DM, Berger MF, Zehir A, Arcila ME, Kris MG, Drilon AE, Ladanyi M. Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays. Journal of Clinical Oncology. 36: 12076-12076. DOI: 10.1200/JCO.2018.36.15_SUPPL.12076 |
0.01 |
|
| 2018 |
Zehir A, Ptashkin R, Mandelker D, Coombs CC, Bolton KL, Yelskaya Z, Hyman DM, Solit DB, Baselga J, Zhang L, Arcila ME, Ladanyi M, Levine RL, Berger MF. Confounding effects of clonal hematopoiesis in clinical genomic profiling of solid tumors. Journal of Clinical Oncology. 36: 12004-12004. DOI: 10.1200/jco.2018.36.15_suppl.12004 |
0.01 |
|
| 2018 |
Bauer TM, Gounder MM, Weise AM, Schwartz GK, Carvajal RD, Kumar P, Zernovak O, Beck A, Doyle J, Mendell-Harary J, Kochan JP, Chen S, LoRusso P, Tap WD, Somaiah N, ... Hyman DM, et al. A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L). Journal of Clinical Oncology. 36: 11514-11514. DOI: 10.1200/JCO.2018.36.15_SUPPL.11514 |
0.01 |
|
| 2018 |
Bolton K, Ptashkin R, Braunstein L, Kelly D, Devlin SM, Coombs CC, Moarii M, Patel M, Bernard E, Berthon A, Glodzik D, Walsh MF, Mandelker D, Patel A, Schulman J, ... ... Hyman DM, et al. Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis Blood. 132: 747-747. DOI: 10.1182/Blood-2018-99-119530 |
0.01 |
|
| 2018 |
Durham BH, Lopez-Rodrigo E, Abramson DH, Picarsic J, Pastore A, Mandelker D, Walsh MF, Arcila ME, Ladanyi M, Solit D, Berger MF, Hyman DM, Ki M, Dunkel I, Geissmann F, et al. Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms Blood. 132: 49-49. DOI: 10.1182/BLOOD-2018-99-114248 |
0.01 |
|
| 2018 |
Dos Santos Fernandes G, Chatila W, Yaeger R, Mendelsohn R, Stadler Z, Segal N, Varghese A, Reidy D, Diaz L, Shia J, Vakiani E, Hechtman J, Schultz N, Berger M, Hyman D, et al. Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically? Annals of Oncology. 29: viii197. DOI: 10.1093/ANNONC/MDY281.137 |
0.01 |
|
| 2018 |
Ou S, Cho B, Kim D, Drilon A, Lee J, Lin J, Zhu V, Ahn M, Camidge D, Stopatschinskaja SS, Liu J, Cui J, Hyman D, Doebele R, Shaw A. OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S1047. DOI: 10.1016/J.JTHO.2018.10.019 |
0.01 |
|
| 2018 |
Lin J, Kim D, Drilon A, Doebele R, Lee J, Zhu V, Ahn M, Lim J, Stopatschinskaja S, Cui J, Hyman D, Camidge R, Ou S, Shaw A, Cho B. OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC Journal of Thoracic Oncology. 13: S322. DOI: 10.1016/J.JTHO.2018.08.240 |
0.01 |
|
| 2017 |
Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. Jco Precision Oncology. 1. PMID 32913969 DOI: 10.1200/PO.17.00181 |
0.01 |
|
| 2017 |
Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, Gundem G, Tian K, Geiger H, Redfield K, Behr G, Benayed R, Zehir A, Hechtman JF, Darnell RB, ... ... Hyman DM, et al. Successful Targeted Therapy of Refractory PediatricFusion-Positive Secretory Breast Carcinoma. Jco Precision Oncology. 2017. PMID 29623306 DOI: 10.1200/PO.17.00034 |
0.01 |
|
| 2017 |
Vaughan EM, Moreno JP, Hyman D, Chen TA, Foreyt JP. Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings. Archives of General Internal Medicine. 1: 17-22. PMID 29517061 |
0.01 |
|
| 2017 |
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, ... ... Hyman DM, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery. PMID 29247021 DOI: 10.1158/2159-8290.Cd-17-1119 |
0.01 |
|
| 2017 |
Chang MT, Shrestha Bhattarai T, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, ... ... Hyman DM, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discovery. PMID 29247016 DOI: 10.1158/2159-8290.Cd-17-0321 |
0.01 |
|
| 2017 |
Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (New York, N.Y.). PMID 29217585 DOI: 10.1126/Science.Aao4572 |
0.01 |
|
| 2017 |
Vaughan EM, Johnston CA, Hyman DJ, Hernandez DC, Hemmige V, Foreyt JP. Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes. Journal of Primary Care & Community Health. 2150131917745760. PMID 29216790 DOI: 10.1177/2150131917745760 |
0.01 |
|
| 2017 |
Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, ... ... Hyman DM, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. Jama Oncology. PMID 29188284 DOI: 10.1001/Jamaoncol.2017.5029 |
0.01 |
|
| 2017 |
Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, ... ... Hyman DM, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discovery. PMID 29122777 DOI: 10.1158/2159-8290.Cd-17-0787 |
0.01 |
|
| 2017 |
Tao JJ, Schram AM, Hyman DM. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine. PMID 29120700 DOI: 10.1146/annurev-med-062016-050343 |
0.01 |
|
| 2017 |
Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB. Clinical and molecular characterization of patients with cancers of unknown primary in the modern era. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29045506 DOI: 10.1093/Annonc/Mdx545 |
0.01 |
|
| 2017 |
Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, et al. Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition. Cancer Research. PMID 28951457 DOI: 10.1158/0008-5472.CAN-17-0768 |
0.01 |
|
| 2017 |
Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J, D'Andrea G, Baxi S, Janjigian Y, Tap W, Dickler M, Baselga J, Taylor BS, ... ... Hyman DM, et al. Oncologist use and perception of large panel next-generation tumor sequencing. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 2298-2304. PMID 28911072 DOI: 10.1093/Annonc/Mdx294 |
0.01 |
|
| 2017 |
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, ... ... Hyman DM, et al. OncoKB: A Precision Oncology Knowledge Base. Jco Precision Oncology. 2017. PMID 28890946 |
0.01 |
|
| 2017 |
Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, ... ... Hyman DM, et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. Jama. 318: 825-835. PMID 28873162 DOI: 10.1001/Jama.2017.11137 |
0.01 |
|
| 2017 |
Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clinical Nuclear Medicine. PMID 28872549 DOI: 10.1097/Rlu.0000000000001820 |
0.01 |
|
| 2017 |
Britt CJ, Hyman D, Hartig GK. Use of sialendoscopy as an aid to identify a large retained foreign body. Ear, Nose, & Throat Journal. 96: E18-E19. PMID 28846794 |
0.01 |
|
| 2017 |
Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. Jco Precision Oncology. 2017. PMID 28825054 |
0.01 |
|
| 2017 |
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell. PMID 28803919 DOI: 10.1016/J.Stem.2017.07.010 |
0.01 |
|
| 2017 |
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Hyman DM, et al. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. 23: 1004. PMID 28777785 DOI: 10.1038/nm0817-1004c |
0.01 |
|
| 2017 |
Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, ... ... Hyman DM, et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28765325 DOI: 10.1158/1078-0432.CCR-17-0544 |
0.01 |
|
| 2017 |
Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Schultz N, Klimstra DS, Zehir A, Abou-Alfa GK, Allen PJ, Harding JJ, Hechtman JF, Jarnagin WR, Varghese AM, Yu KH, Schattner M, ... Hyman DM, et al. Real Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28754816 DOI: 10.1158/1078-0432.Ccr-17-0899 |
0.01 |
|
| 2017 |
Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, Arcila ME, Dogan S, Klimstra DS, Ladanyi M, Jungbluth AA. Pan-Trk Immunohistochemistry is an Efficient and Reliable Screen for the Detection of NTRK Fusions. The American Journal of Surgical Pathology. PMID 28719467 DOI: 10.1097/PAS.0000000000000911 |
0.01 |
|
| 2017 |
Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, ... ... Hyman DM, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discovery. PMID 28578312 DOI: 10.1158/2159-8290.Cd-17-0507 |
0.01 |
|
| 2017 |
Schram AM, Hyman DM. Quantifying the Benefits of Genome-Driven Oncology. Cancer Discovery. 7: 552-554. PMID 28576841 DOI: 10.1158/2159-8290.CD-17-0380 |
0.01 |
|
| 2017 |
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017730143. PMID 28489509 DOI: 10.1200/Jco.2017.73.0143 |
0.01 |
|
| 2017 |
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Hyman DM, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. PMID 28481359 DOI: 10.1038/Nm.4333 |
0.01 |
|
| 2017 |
Hyman DJ. Hypertension: Does Polypharmacy Lead to Nonadherence or Nonadherence to Polypharmacy? Hypertension (Dallas, Tex. : 1979). PMID 28461603 DOI: 10.1161/HYPERTENSIONAHA.117.09334 |
0.01 |
|
| 2017 |
Hyman DJ, Pavlik V. Controlling Hypertension: We Have the Tools-We Just Need to Use Them. Journal of General Internal Medicine. PMID 28455646 DOI: 10.1007/s11606-017-4060-8 |
0.01 |
|
| 2017 |
Jordan EJ, Kim HR, Arcila ME, Barron DA, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, ... ... Hyman DM, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery. PMID 28336552 DOI: 10.1158/2159-8290.CD-16-1337 |
0.01 |
|
| 2017 |
Soumerai JD, Zelenetz AD, Moskowitz C, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz S, Portlock C, Konner J, Gounder MM, Hyman DM, et al. The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28314788 DOI: 10.1158/1078-0432.CCR-16-3068 |
0.01 |
|
| 2017 |
Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, ... ... Hyman DM, et al. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs. PMID 28281183 DOI: 10.1007/S10637-017-0445-0 |
0.01 |
|
| 2017 |
Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, et al. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. PMID 28274957 DOI: 10.1158/2159-8290.Cd-16-1431 |
0.01 |
|
| 2017 |
Schram AM, Aghajanian CA, Hyman DM. Niraparib in Recurrent Ovarian Cancer. The New England Journal of Medicine. 376: 801. PMID 28229583 |
0.01 |
|
| 2017 |
Schram AM, Berger MF, Hyman DM. Precision oncology: Charting a path forward to broader deployment of genomic profiling. Plos Medicine. 14: e1002242. PMID 28222135 DOI: 10.1371/journal.pmed.1002242 |
0.01 |
|
| 2017 |
Narayan V, Keefe SM, Haas N, Wang L, Puzanov I, Putt ME, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, et al. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28196874 DOI: 10.1158/1078-0432.Ccr-16-2869 |
0.01 |
|
| 2017 |
Hyman DM, Taylor BS, Baselga J. Implementing Genome-Driven Oncology. Cell. 168: 584-599. PMID 28187282 DOI: 10.1016/j.cell.2016.12.015 |
0.01 |
|
| 2017 |
Teo MY, Bambury R, Zabor EC, Jordan EJ, Al-Ahmadie HA, Boyd M, Bouvier N, Mullane S, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, et al. DNA Damage Response and Repair Gene Alterations Are Associated With Improved Survival In Patients With Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28137924 DOI: 10.1158/1078-0432.Ccr-16-2520 |
0.01 |
|
| 2017 |
Narayan HK, Finkelman BS, French B, Plappert T, Hyman D, Smith AM, Margulies KB, Ky B. Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Followup. Circulation. PMID 28104715 DOI: 10.1161/Circulationaha.116.023463 |
0.01 |
|
| 2017 |
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic Oncology. 144: 96-100. PMID 28094040 DOI: 10.1016/J.Ygyno.2016.10.036 |
0.01 |
|
| 2017 |
Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, Demetri GD, El-Deiry WS, Lassen UN, Dowlati A, Brose MS, Boni V, Turpin B, Nagasubramanian R, Cruickshank S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. Journal of Clinical Oncology. 35: LBA2501-LBA2501. DOI: 10.1200/Jco.2017.35.18_Suppl.Lba2501 |
0.01 |
|
| 2017 |
Liu D, Dang TO, Harnicar S, Kargus K, Evans LA, So-Kwan YY, Hyman DM. Integrating clinical pharmacy services into patient care in an early-phase clinical trial clinic. Journal of Clinical Oncology. 35: e18228-e18228. DOI: 10.1200/JCO.2017.35.15_SUPPL.E18228 |
0.01 |
|
| 2017 |
Cadoo KA, DeLair D, Mandelker D, Trottier M, Stewart C, Tran C, Kemel Y, Walsh MF, Scharf F, Hyman DM, Joseph V, Robson ME, Abu-Rustum N, Offit K, Solit DB, et al. Somatic tumor profiling of DNA mismatch repair (MMR) deficient endometrial cancers (EC). Journal of Clinical Oncology. 35: e17121-e17121. DOI: 10.1200/jco.2017.35.15_suppl.e17121 |
0.01 |
|
| 2017 |
D'souza A, Shishedo S, Spicer DV, Welter L, Jiang Y, Hyman DM, Solit DB, Ma CX, Bose R, Cutler RE, Eli L, Hicks JB, Kuhn P, Lu JM. Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib. Journal of Clinical Oncology. 35: e12554-e12554. DOI: 10.1200/Jco.2017.35.15_Suppl.E12554 |
0.01 |
|
| 2017 |
Subbiah V, Gervais R, Riely GJ, Hollebecque A, Blay J, Felip E, Schuler MH, Goncalves A, Italiano A, Keedy VL, Chau I, Puzanov I, Raje N, Makrutzki M, Riehl T, ... ... Hyman DM, et al. Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. Journal of Clinical Oncology. 35: 9074-9074. DOI: 10.1200/JCO.2017.35.15_SUPPL.9074 |
0.01 |
|
| 2017 |
Aghajanian C, DeLair D, Grisham RN, Hensley ML, Konner JA, Makker V, O'Cearbhaill RE, Sabbatini P, Soumerai T, Snyder Charen A, Spriggs DR, Soslow RA, Tew WP, Zamarin D, Robson ME, ... ... Hyman DM, et al. Somatic mutations in homologous recombination pathway genes in ovarian cancer. Journal of Clinical Oncology. 35: 5545-5545. DOI: 10.1200/Jco.2017.35.15_Suppl.5545 |
0.01 |
|
| 2017 |
Carlo MI, Mukherjee S, Kemel Y, Zhang L, Mandelker D, Vijai J, Coskey DT, Pradhan N, Hyman DM, Hakimi AA, Coleman J, Lee C, Feldman DR, Voss MH, Offit K, et al. Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC). Journal of Clinical Oncology. 35: 4524-4524. DOI: 10.1200/Jco.2017.35.15_Suppl.4524 |
0.01 |
|
| 2017 |
Lowery MA, Jordan E, Kemel Y, Mukherjee S, Cercek A, Kemeny NE, Varghese AM, Rusek M, Boucher TM, Mandelker D, Berger MF, Ptashkin R, Hyman DM, Klimstra D, Saltz L, et al. A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC). Journal of Clinical Oncology. 35: 4085-4085. DOI: 10.1200/jco.2017.35.15_suppl.4085 |
0.01 |
|
| 2017 |
Li BT, Janku F, Patel MR, Sullivan RJ, Flaherty K, Buchbinder EI, Lacouture ME, Varghese AM, Wong DJL, Sznol M, Sosman JA, Keedy VL, Wang-Gillam A, Ribas A, Tolcher AW, ... ... Hyman DM, et al. First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. Journal of Clinical Oncology. 35: 2508-2508. DOI: 10.1200/Jco.2017.35.15_Suppl.2508 |
0.01 |
|
| 2017 |
Hyman DM, Kaley TJ, Hollebecque A, Subbiah V, Rodon Ahnert J, Lockhart AC, Keedy VL, Hofheinz R, Joly Lobbedez F, Blay J, Chau I, Puzanov I, Raje N, Wolf J, Makrutzki M, et al. Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study. Journal of Clinical Oncology. 35: 2004-2004. DOI: 10.1200/JCO.2017.35.15_SUPPL.2004 |
0.01 |
|
| 2017 |
Varghese AM, Moore KN, Hamilton EP, Hyman DM, Jhaveri KL, Wang XA, Callies S, Fink AA, Wacheck V, Bendell JC. Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients. Journal of Clinical Oncology. 35: 1064-1064. DOI: 10.1200/JCO.2017.35.15_SUPPL.1064 |
0.01 |
|
| 2017 |
Hanker A, Brewer MR, Sheehan J, Koch J, Lanman R, Hyman D, Cutler R, Lalani A, Cross D, Lovly C, Meiler J, Arteaga C. Abstract P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-03 |
0.01 |
|
| 2017 |
Schram A, Won HH, Andre F, Arnedos M, Bernstam FM, Bedard PL, Shaw KR, Horlings H, Micheel C, Park BH, Mann G, Lalani AS, Smyth L, Solit DB, Schrag D, ... ... Hyman DM, et al. Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-103 |
0.01 |
|
| 2017 |
Sullivan RJ, Janku F, Li BT, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman DM, Flaherty KT, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, et al. Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct003 |
0.01 |
|
| 2017 |
Hyman DM, Piha-Paul SA, Rodon J, Saura C, Shapiro GI, Quinn DI, Moreno V, Mayer IA, Arteaga C, Boni V, Calvo E, Loi S, Lockhart AC, Smyth LM, Erinjeri J, et al. Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct001 |
0.01 |
|
| 2017 |
Penson A, Camacho N, Varghese AM, Abeshouse A, Razavi P, Syed A, Zehir A, Schultz N, Solit DB, Hyman D, Taylor BS, Berger MF. Abstract 971: Genome directed diagnosis informs clinical cancer care Cancer Research. 77: 971-971. DOI: 10.1158/1538-7445.Am2017-971 |
0.01 |
|
| 2017 |
Lipsyc M, Chatila W, Hechtman JF, Sanchez-Vega F, Middha S, Cercek A, Stadler Z, Kundra R, Syed A, Hyman DM, Zehir A, Shahrokni A, Varghese A, Reidy D, Segal NH, et al. Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer Cancer Research. 77: 4380-4380. DOI: 10.1158/1538-7445.Am2017-4380 |
0.01 |
|
| 2017 |
Schram AM, Reales D, Galle J, Cambria R, Durany R, Feldman D, Sherman E, Rosenberg J, D'Andrea G, Baxi S, Janjigian Y, Tap W, Dickler M, Baselga J, Taylor B, ... ... Hyman DM, et al. Abstract 375: Oncologist use and perception of large panel next generation tumor sequencing Cancer Research. 77: 375-375. DOI: 10.1158/1538-7445.Am2017-375 |
0.01 |
|
| 2017 |
Bhatia A, Ulaner G, Rampal R, Hyman D, Abdel-Wahab O, Durham B, Hajdenberg J, Ganzel C, Diamond E. RARE-22. SINGLE-AGENT DABRAFENIB FOR INTRACRANIAL BRAFV600E-MUTATED HISTIOCYTOSIS Neuro-Oncology. 19: vi215-vi215. DOI: 10.1093/neuonc/nox168.869 |
0.01 |
|
| 2017 |
Makker V, Boucicaut N, Cadoo K, Grisham R, Hyman D, O'Cearbhail R, Snyder Charen A, Tew W, Martin M, Aghajanian C. A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC) Annals of Oncology. 28: v346. DOI: 10.1093/ANNONC/MDX372.041 |
0.01 |
|
| 2017 |
Li B, Shen R, Buonocore D, Olah Z, Ni A, Ginsberg M, Ulaner G, Weber W, Tsui D, Offin M, Won H, Ladanyi M, Riely G, Solit D, Hyman D, et al. OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers Journal of Thoracic Oncology. 12: S1783. DOI: 10.1016/J.Jtho.2017.09.410 |
0.01 |
|
| 2016 |
Paik M, Black B, Hyman DA. Damage caps and defensive medicine, revisited. Journal of Health Economics. 51: 84-97. PMID 28129637 DOI: 10.1016/j.jhealeco.2016.11.001 |
0.01 |
|
| 2016 |
Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of ERBB2 (Human Epidermal Growth Factor Receptor 2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. The Journal of Molecular Diagnostics : Jmd. PMID 28027945 DOI: 10.1016/J.Jmoldx.2016.09.010 |
0.01 |
|
| 2016 |
Schram AM, Iasonos A, Hyman DM. Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4312-4314. PMID 27998226 DOI: 10.1200/JCO.2016.69.7169 |
0.01 |
|
| 2016 |
Schram AM, Voss MH, Hyman DM. Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016705061. PMID 27918716 DOI: 10.1200/JCO.2016.70.5061 |
0.01 |
|
| 2016 |
Gostin LO, Hyman DA, Jacobson PD. The Affordable Care Act: Moving Forward in the Coming Years. Jama. PMID 27893878 DOI: 10.1001/Jama.2016.18908 |
0.01 |
|
| 2016 |
Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, Iasonos A. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016699751. PMID 27893325 DOI: 10.1200/JCO.2016.69.9751 |
0.01 |
|
| 2016 |
Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, You D, Gasmi B, Viale A, Chapman PB. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. PMID 27863426 DOI: 10.18632/oncotarget.13397 |
0.01 |
|
| 2016 |
Yang C, Arnold AG, Trottier M, Sonoda Y, Abu-Rustum NR, Zivanovic O, Robson ME, Stadler ZK, Walsh MF, Hyman DM, Offit K, Zhang L. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. Breast Cancer Research and Treatment. PMID 27757719 DOI: 10.1007/s10549-016-4021-7 |
0.01 |
|
| 2016 |
Whelton PK, Einhorn PT, Muntner P, Appel LJ, Cushman WC, Diez Roux AV, Ferdinand KC, Rahman M, Taylor HA, Ard J, Arnett DK, Carter BL, Davis BR, Freedman BI, Cooper LA, ... ... Hyman DJ, et al. Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension (Dallas, Tex. : 1979). PMID 27620388 DOI: 10.1161/Hypertensionaha.116.07905 |
0.01 |
|
| 2016 |
Manus MK, Roy S, Stag R, Hyman D. Non-compaction cardiomyopathy in an asymptomatic athlete. Bmj Case Reports. 2016. PMID 27535732 DOI: 10.1136/bcr-2016-216339 |
0.01 |
|
| 2016 |
Diamond EL, Hatzoglou V, Patel S, Abdel-Wahab O, Rampal R, Hyman DM, Holodny AI, Raj A. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet Journal of Rare Diseases. 11: 109. PMID 27484739 DOI: 10.1186/S13023-016-0490-3 |
0.01 |
|
| 2016 |
Morris LG, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG, Wong RJ, Lee NY, Sherman EJ, Baxi SS, Ganly I, Singh B, Shah JP, Shaha AR, Boyle JO, ... ... Hyman DM, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. Jama Oncology. PMID 27442865 DOI: 10.1001/Jamaoncol.2016.1790 |
0.01 |
|
| 2016 |
Hyman DA, Saha S, Nayar HS, Doyle JF, Agarwal SK, Chaiet SR. Patterns of Facial Fractures and Protective Device Use in Motor Vehicle Collisions From 2007 to 2012. Jama Facial Plastic Surgery. PMID 27441732 DOI: 10.1001/jamafacial.2016.0733 |
0.01 |
|
| 2016 |
Ulaner GA, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri J, Solomon S, Kolb H, Lyashchenko S, Lewis J, Carrasquillo J. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using the 89Zr-DFO-trastuzumab PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27151988 DOI: 10.2967/Jnumed.115.172031 |
0.01 |
|
| 2016 |
Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. Jacc. Cardiovascular Imaging. PMID 27085442 DOI: 10.1016/J.Jcmg.2015.11.024 |
0.01 |
|
| 2016 |
Hyman DM, Eaton A, Ivy SP, Spriggs DR, Iasonos A. Measuring Toxicity in Phase I Clinical Trials-Letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1828. PMID 27037257 DOI: 10.1158/1078-0432.CCR-15-3043 |
0.01 |
|
| 2016 |
Eubank MH, Hyman DM, Kanakamedala AD, Gardos SM, Wills JM, Stetson PD. Automated eligibility screening and monitoring for genotype-driven precision oncology trials. Journal of the American Medical Informatics Association : Jamia. PMID 27016727 DOI: 10.1093/jamia/ocw020 |
0.01 |
|
| 2016 |
Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer. PMID 26916138 DOI: 10.1002/cncr.29918 |
0.01 |
|
| 2016 |
Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, et al. What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26884591 DOI: 10.1093/annonc/mdw042 |
0.01 |
|
| 2016 |
Hyman DM, Solit DB, Iasonos A. Reply to M.P. Decatris et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 887. PMID 26755514 DOI: 10.1200/JCO.2015.65.2487 |
0.01 |
|
| 2016 |
Abida W, Brennan R, Armenia J, Curtis KR, Gopalan A, Arcila ME, Danila DC, Rathkopf DE, Morris MJ, Slovin SF, Solit DB, Hyman DM, Durack JC, Solomon SB, Reuter VE, et al. Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay. Journal of Clinical Oncology. 34: 254-254. DOI: 10.1200/JCO.2016.34.2_SUPPL.254 |
0.01 |
|
| 2016 |
Grisham RN, Giri DD, Iasonos A, Zhou Q, Girshman J, McGrath SP, Orodel O, O'Cearbhaill RE, Mills NE, Troso-Sandoval TA, Sabbatini P, Tew WP, Hyman DM, Hensley ML, Zamarin D, et al. Phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior therapies. Journal of Clinical Oncology. 34: TPS5602-TPS5602. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5602 |
0.01 |
|
| 2016 |
Drilon AE, Hong DS, Cruickshank S, Deegan M, Ku N, Hyman DM. A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors. Journal of Clinical Oncology. 34: TPS2599-TPS2599. DOI: 10.1200/JCO.2016.34.15_SUPPL.TPS2599 |
0.01 |
|
| 2016 |
Harding JJ, Heins ZJ, Connell LC, Soumerai T, Kemeny NE, Jarnagin WR, O'Reilly EM, DeMatteo RP, D'Angelica MI, Lowery MA, Kingham TP, Gambarin M, Hyman DM, LY M, Hamilton CR, et al. Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 34: e15635-e15635. DOI: 10.1200/JCO.2016.34.15_SUPPL.E15635 |
0.01 |
|
| 2016 |
Jordan E, Barron D, Schultz N, Chakravarty D, Kris MG, Rudin CM, Li BT, Yu HA, Drilon AE, Rusch VW, Baselga J, Taylor BS, Hyman DM, Solit DB, Ladanyi M, et al. Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection. Journal of Clinical Oncology. 34: 9084-9084. DOI: 10.1200/jco.2016.34.15_suppl.9084 |
0.01 |
|
| 2016 |
Rusch VW, Tan KS, Ghanie A, Arcila ME, Travis WD, Jones DR, Park BJ, Huang J, Rudin CM, Hyman DM, Solit DB, Berger MF, Baselga J, Ladanyi M, Riely GJ. Next generation sequencing (NGS) in resectable non-small cell lung cancer (NSCLC): Therapeutic implications. Journal of Clinical Oncology. 34: 8541-8541. DOI: 10.1200/JCO.2016.34.15_suppl.8541 |
0.01 |
|
| 2016 |
Grisham RN, Chiang S, Shen R, Murali R, Shu CA, Levine DA, Soumerai T, Hyman DM, Hensley ML, Berger MF, Aghajanian C, Iyer G. Characterization of actionable somatic alterations in microdissected gynecologic carcinosarcomas. Journal of Clinical Oncology. 34: 5594-5594. DOI: 10.1200/JCO.2016.34.15_SUPPL.5594 |
0.01 |
|
| 2016 |
Hyman DM, Rasco DW, Infante JR, Liu JF, Welkowsky E, Thai DL, Haqq CM. Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. Journal of Clinical Oncology. 34: 5536-5536. DOI: 10.1200/JCO.2016.34.15_SUPPL.5536 |
0.01 |
|
| 2016 |
Jordan E, Lowery MA, Ptashkin R, Zehir A, Berger MF, Maynard H, Glassman DC, Covington CM, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, et al. Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype. Journal of Clinical Oncology. 34: 4127-4127. DOI: 10.1200/Jco.2016.34.15_Suppl.4127 |
0.01 |
|
| 2016 |
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Kemeny NE, O'Reilly EM, Jarnagin WR, Harding JJ, DeMatteo RP, D'Angelica MI, Cercek A, LY M, Salehi E, Hechtman JF, ... ... Hyman DM, et al. Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention. Journal of Clinical Oncology. 34: 4088-4088. DOI: 10.1200/JCO.2016.34.15_SUPPL.4088 |
0.01 |
|
| 2016 |
Gounder MM, Bauer TM, Schwartz GK, Masters T, Carvajal RD, Song S, Kumar P, Gajee R, Zernovak O, Rosen MM, Kochan JP, Chen S, Hyman DM, Gokmen S, Meric-Bernstam F, et al. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. Journal of Clinical Oncology. 34: 2581-2581. DOI: 10.1200/JCO.2016.34.15_SUPPL.2581 |
0.01 |
|
| 2016 |
Hyman DM, Tran B, Corral Jaime J, Garralda E, Machiels JH, Schellens JHM, Bedard P, Campone M, Cassier P, Sarantopoulos J, Vaishampayan UN, Chugh R, Mahipal A, Lockhart AC, Sessa C, et al. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors. Journal of Clinical Oncology. 34: 2500-2500. DOI: 10.1200/Jco.2016.34.15_Suppl.2500 |
0.01 |
|
| 2016 |
Zehir A, Coombs CC, Devlin S, Kishtagari A, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Tallman MS, Levine RL, Berger MF. Prevalence of clonal hematopoiesis in patients with advanced cancer. Journal of Clinical Oncology. 34: 1511-1511. DOI: 10.1200/Jco.2016.34.15_Suppl.1511 |
0.01 |
|
| 2016 |
Smyth LM, Reichel JB, Tang J, Patel JAA, Meng F, Selcuklu SD, You D, Samoila A, Schiavon G, Li BT, Razavi P, Piscuoglio S, Reis-Filho JS, Hudis CA, Baselga J, ... ... Hyman DM, et al. Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). Journal of Clinical Oncology. 34: 11500-11500. DOI: 10.1200/Jco.2016.34.15_Suppl.11500 |
0.01 |
|
| 2016 |
Durham BH, Yoshimi A, Papo M, Chung YR, Ozkaya N, Ganzel C, Dogan A, Hyman DM, Park CY, Rampal RK, Roos Weil D, Lemoine FM, Amoura Z, Bernard OA, Diamond EL, et al. Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses Blood. 128: 951-951. DOI: 10.1182/Blood.V128.22.951.951 |
0.01 |
|
| 2016 |
Diamond EL, Subbiah V, Lockhart C, Blay J, Faris JE, Puzanov I, Chau I, Raje NS, Wolf JS, Erinjeri J, Torrisi J, Ulaner G, Lacouture M, Robson S, Makrutzki M, ... ... Hyman DM, et al. Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study Blood. 128: 480-480. DOI: 10.1182/BLOOD.V128.22.480.480 |
0.01 |
|
| 2016 |
Coombs CC, Zehir A, Devlin S, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Tallman MS, Levine RL, Berger M. Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles Blood. 128: 37-37. DOI: 10.1182/Blood.V128.22.37.37 |
0.01 |
|
| 2016 |
Razavi P, Chang MT, Middha S, Ross DS, Zehir A, Proverbs-Singh TA, Kandoth C, Chandarlapaty S, Dickler MN, Reis-Filho JS, Patil S, Seshan V, Smyth L, Iyengar NM, Jhaveri K, ... ... Hyman D, et al. Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations Cancer Research. 76: 4509-4509. DOI: 10.1158/1538-7445.Am2016-4509 |
0.01 |
|
| 2016 |
Coombs C, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman D, Solit D, Robson M, Baselga J, Arcila M, Tallman M, Levine R, Berger M. Abstract 2640: Clonal hematopoiesis identified by matched-normal blood sequencing of solid tumor patients without hematologic malignancy is common and is associated with decreased overall survival Epidemiology. 76: 2640-2640. DOI: 10.1158/1538-7445.Am2016-2640 |
0.01 |
|
| 2016 |
Drilon A, Hong D, Deeken J, Smith S, Reynolds M, Cruickshank S, Deegan M, Ku N, Hyman D. A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors Annals of Oncology. 27: vi132. DOI: 10.1093/annonc/mdw368.52 |
0.01 |
|
| 2016 |
Drilon A, Garralda E, Stathis A, Szyldergemajn S, Hyman D, Boni V, Griguolo G, Martinez EJ, Makker V, Canziani L, Teruel CF, Soto-Matos A, Sessa C, Calvo E. Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors Annals of Oncology. 27: vi125. DOI: 10.1093/annonc/mdw368.34 |
0.01 |
|
| 2016 |
Hyman D, Chatterjee M, Langenberg M, Lin C, Suárez C, Tai D, Cassier P, Yamamoto N, De Weger V, Jeay S, Meille C, Halilovic E, Mariconti L, Guerreiro N, Kumar A, et al. Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors European Journal of Cancer. 69: S128-S129. DOI: 10.1016/S0959-8049(16)32982-3 |
0.01 |
|
| 2016 |
Scaltriti M, Carmona F, Toska E, Cocco E, Hyman D, Cutler R, Avogadri-Connors F, Wick M, Papadopoulos K, Lalani A, Baselga J. Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy European Journal of Cancer. 69: S125. DOI: 10.1016/S0959-8049(16)32971-9 |
0.01 |
|
| 2016 |
Kovacic WE, Hyman DA. Consume or invest: What do/should agency leaders maximize? Washington Law Review. 91: 295-324. |
0.01 |
|
| 2015 |
Davenport SM, Suidan RS, Huang J, Hyman DM, Chi DS. Primary debulking surgery for metastatic cervical adenocarcinoma: A case report. Gynecologic Oncology Reports. 14: 23-5. PMID 26793767 DOI: 10.1016/j.gore.2015.09.004 |
0.01 |
|
| 2015 |
Hechtman JF, Zehir A, Yaeger RD, Wang L, Middha S, Zheng T, Hyman D, Solit D, Arcila ME, Borsu L, Shia J, Vakiani E, Saltz L, Ladanyi M. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma that are Preferentially Associated with Wild Type RAS/RAF. Molecular Cancer Research : McR. PMID 26660078 DOI: 10.1158/1541-7786.Mcr-15-0392-T |
0.01 |
|
| 2015 |
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, ... ... Hyman DM, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery. PMID 26566875 DOI: 10.1182/Blood.V126.23.481.481 |
0.01 |
|
| 2015 |
Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman D, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. Jama Oncology. 1-8. PMID 26556299 DOI: 10.1001/jamaoncol.2015.5208 |
0.01 |
|
| 2015 |
Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, et al. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 26509849 DOI: 10.1097/IGC.0000000000000559 |
0.01 |
|
| 2015 |
Eaton A, Iasonos A, Gounder MM, Pamer EG, Drilon A, Vulih D, Smith GL, Ivy SP, Spriggs DR, Hyman DM. Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26324741 DOI: 10.1158/1078-0432.CCR-15-0339 |
0.01 |
|
| 2015 |
Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, et al. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26324360 DOI: 10.1200/JCO.2015.62.4726 |
0.01 |
|
| 2015 |
Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today. PMID 26320725 DOI: 10.1016/j.drudis.2015.08.005 |
0.01 |
|
| 2015 |
Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England Journal of Medicine. 373: 726-36. PMID 26287849 DOI: 10.1056/NEJMoa1502309 |
0.01 |
|
| 2015 |
Marcus BC, Hyman D. Evidence-Based Medicine in Laser Medicine for Facial Plastic Surgery. Facial Plastic Surgery Clinics of North America. 23: 297-302. PMID 26208768 DOI: 10.1016/j.fsc.2015.04.003 |
0.01 |
|
| 2015 |
Hyman DM, Solit DB. Tumor Genetic Screening Programs: A Call to Action. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2725-6. PMID 26195721 DOI: 10.1200/JCO.2015.61.9296 |
0.01 |
|
| 2015 |
Hyman DA, Studdert DM. Emergency Medical Treatment and Labor Act: what every physician should know about the federal antidumping law. Chest. 147: 1691-6. PMID 26033130 DOI: 10.1378/chest.14-2046 |
0.01 |
|
| 2015 |
Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, Rosales N, Monette S, Wang A, Hyman DM, Levine DA, Solit D, Spriggs DR. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. Plos One. 10: e0126633. PMID 25965947 DOI: 10.1371/journal.pone.0126633 |
0.01 |
|
| 2015 |
Pavlik VN, Chan W, Hyman DJ, Feldman P, Ogedegbe G, Schwartz JE, McDonald M, Einhorn P, Tobin JN. Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials. Current Hypertension Reviews. PMID 25808682 DOI: 10.2174/1573402111666150325234503 |
0.01 |
|
| 2015 |
Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR. Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget. PMID 25682870 |
0.01 |
|
| 2015 |
Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, et al. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 75: 747-55. PMID 25672916 DOI: 10.1007/s00280-015-2693-z |
0.01 |
|
| 2015 |
Meisel JL, Hyman DM, Jotwani A, Zhou Q, Abu-Rustum NR, Iasonos A, Pike MC, Aghajanian C. The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology. 136: 505-11. PMID 25546114 DOI: 10.1016/J.Ygyno.2014.12.026 |
0.01 |
|
| 2015 |
Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discovery. 5: 64-71. PMID 25324352 DOI: 10.1182/Blood.V124.21.1833.1833 |
0.01 |
|
| 2015 |
Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. Journal of Human Hypertension. 29: 213-8. PMID 25209307 DOI: 10.1038/jhh.2014.73 |
0.01 |
|
| 2015 |
Iyer G, Bagrodia A, Cha EK, Boyd ME, Zehir A, Cheng DT, Hyman DM, Bambury RM, Arcila ME, Ladanyi M, Viale A, Al-Ahmadie H, Berger MF, Bochner BH, Rosenberg JE, et al. Comparison of genetic alterations from the bladder cancer genome atlas (TCGA) and a prospective set of high-grade urothelial carcinoma tumors using a CLIA laboratory next generation sequencing assay. Journal of Clinical Oncology. 33: 298-298. DOI: 10.1200/JCO.2015.33.7_SUPPL.298 |
0.01 |
|
| 2015 |
Arcila ME, Yu HA, Drilon AE, Riely GJ, Zehir A, Sadowska J, Hyman DM, Kris MG, Berger MF, Ladanyi M. Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay. Journal of Clinical Oncology. 33: e22160-e22160. DOI: 10.1200/JCO.2015.33.15_SUPPL.E22160 |
0.01 |
|
| 2015 |
Eaton A, Iasonos A, Gounder MM, Pamer E, Drilon AE, Vulih D, Smith GL, Ivy P, Spriggs DR, Hyman DM. Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities. Journal of Clinical Oncology. 33: e17674-e17674. DOI: 10.1200/JCO.2015.33.15_SUPPL.E17674 |
0.01 |
|
| 2015 |
Hyman DM, Sill M, Cho JK, Lankes HA, Piekarz R, Hensley ML. A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16512 |
0.01 |
|
| 2015 |
Ross DS, Zehir A, Cheng DT, Nafa K, Jour G, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays. Journal of Clinical Oncology. 33: 604-604. DOI: 10.1200/Jco.2015.33.15_Suppl.604 |
0.01 |
|
| 2015 |
Soumerai T, Hyman DM, Murali R, Zehir A, O'Cearbhaill RE, Arcila ME, Aghajanian C, Soslow RA, Solit DB, Hensley ML. Identifying actionable mutations in uterine leiomyosarcoma. Journal of Clinical Oncology. 33: 5586-5586. DOI: 10.1200/JCO.2015.33.15_SUPPL.5586 |
0.01 |
|
| 2015 |
O'Cearbhaill RE, Hyman DM, Tew WP, Iasonos A, Cangemi NA, Aghajanian C, Bell-McGuinn KM, Makker V, Hensley ML, Konner JA, Grisham RN, Diaz-Macinnis K, Sabbatini P, Spriggs DR. Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer. Journal of Clinical Oncology. 33: 5572-5572. DOI: 10.1200/JCO.2015.33.15_SUPPL.5572 |
0.01 |
|
| 2015 |
Bambury RM, Jordan E, Zabor EC, Bouvier N, Al-Ahmadie H, Boyd ME, Mullane SA, Cha EK, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Bajorin DF, Bellmunt J, et al. Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma. Journal of Clinical Oncology. 33: 4532-4532. DOI: 10.1200/Jco.2015.33.15_Suppl.4532 |
0.01 |
|
| 2015 |
Varghese AM, Hyman DM, Zehir A, Vakiani E, Klimstra DS, Ladanyi M, Berger MF, Solit DB, Saltz L. Prospective identification of potentially actionable molecular alterations in cancers of unknown primary. Journal of Clinical Oncology. 33: 4110-4110. DOI: 10.1200/JCO.2015.33.15_SUPPL.4110 |
0.01 |
|
| 2015 |
Drilon AE, Eaton A, Schindler K, Gounder MM, Smith GL, Vulih D, Harris PJ, Spriggs DR, Ivy P, Iasonos A, Lacouture ME, Hyman DM. Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP). Journal of Clinical Oncology. 33: 2546-2546. DOI: 10.1200/JCO.2015.33.15_SUPPL.2546 |
0.01 |
|
| 2015 |
Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, Gomes DaGama E, Uddin M, Chiosis G, et al. Phase I trial of the HSP-90 inhibitor PU-H71. Journal of Clinical Oncology. 33: 2537-2537. DOI: 10.1200/Jco.2015.33.15_Suppl.2537 |
0.01 |
|
| 2015 |
Omuro AMP, Zehir A, Cheng DT, Berger MF, Hyman DM, Solit DB, Baselga J, Ladanyi M, Arcila ME, Hameed M, Sabbatini P, DeAngelis LM, Gutin PH, Rosenblum M, Mellinghoff IK, et al. Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay Journal of Clinical Oncology. 33: 2057-2057. DOI: 10.1200/Jco.2015.33.15_Suppl.2057 |
0.01 |
|
| 2015 |
Schrader KA, Cheng DT, Vijai J, Prasad M, Walsh M, Zehir A, Thomas T, Benayed R, Stadler ZK, Ashraf A, Arcila ME, Solit DB, Hyman DM, Zhang L, Klimstra D, et al. Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases. Journal of Clinical Oncology. 33: 1509-1509. DOI: 10.1200/JCO.2015.33.15_SUPPL.1509 |
0.01 |
|
| 2015 |
Moore KN, Varghese AM, Hyman DM, Callies S, Lin J, Wacheck V, Pant S, Bauer TM, Bendell JC. A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 33: 11075-11075. DOI: 10.1200/JCO.2015.33.15_SUPPL.11075 |
0.01 |
|
| 2015 |
Hechtman JF, Arcila ME, Cheng DT, Solit DB, Yaeger RD, Hyman DM, Berger MF, Shia J, Vakiani E, Zehir A, Ladanyi M. Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay. Journal of Clinical Oncology. 33: 11071-11071. DOI: 10.1200/JCO.2015.33.15_SUPPL.11071 |
0.01 |
|
| 2015 |
Durham BH, Diamond EL, Haroche J, Yao Z, Ma J, Parikh SA, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol J, Campbell P, Walsh MP, Sylvester B, ... ... Hyman DM, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms Blood. 126: 481-481. DOI: 10.1182/blood.V126.23.481.481 |
0.01 |
|
| 2015 |
Raje N, Chau I, Hyman DM, Ribrag V, Blay J, Tabernero J, Elez-Fernandez ME, Wolf JS, Sirzen F, Yee A, Faris J, Kaiser M, Landau H, Michot J, Veronese L, et al. Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study Blood. 126: 4263-4263. DOI: 10.1182/Blood.V126.23.4263.4263 |
0.01 |
|
| 2015 |
Coombs CC, Zehir A, Devlin S, Middha S, Cheng D, Kishtagari A, Hyman DM, Solit D, Robson M, Baselga J, Arcila M, Ladanyi M, Tallman MS, Levine RL, Berger M. Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies Blood. 126: 2447-2447. DOI: 10.1182/Blood.V126.23.2447.2447 |
0.01 |
|
| 2015 |
Garralda E, Stathis A, Drilon A, Boni V, Hyman D, Calvo E, Griguolo G, Makker V, Doger B, Canziani L, Varghese A, Jimenez E, Luque J, Soto-Matos A, Szyldergemajn S, et al. 335 Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors European Journal of Cancer. 51: S66. DOI: 10.1016/S0959-8049(16)30199-X |
0.01 |
|
| 2015 |
Ducie J, Murali R, Hyman D, Hensley M, Soslow R, Zivanovic O. Perivascular epithelioid cell tumor (PEComa) of the gynecologic tract: A single institution clinicopathologic review Gynecologic Oncology. 137: 167. DOI: 10.1016/J.YGYNO.2015.01.419 |
0.01 |
|
| 2015 |
Bagrodia A, Iyer G, Cha E, Boyd M, Zehir A, Cheng D, Hyman D, Al-Ahmadie H, Bambury R, Arcila M, Ladanyi M, Viale A, Michael B, Bochner B, Rosenberg J, et al. Mp64-02 Comparison Of Genetic Alterations From The Cancer Genome Atlas Bladder Cancer Analysis And A Prospective Set Of High-Grade Urothelial Carcinoma Tumors Using A Clinical Laboratory Improvement Amendments-Certified Next Generation Sequencing Assay The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2313 |
0.01 |
|
| 2015 |
Hyman DA, Kovacic WE. Why who does what matters: Governmental design and agency performance George Washington Law Review. 82: 1446-1516. |
0.01 |
|
| 2014 |
Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2372-8. PMID 25281711 DOI: 10.1093/annonc/mdu461 |
0.01 |
|
| 2014 |
Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 124: 3016-9. PMID 25150293 DOI: 10.1182/blood-2014-04-570937 |
0.01 |
|
| 2014 |
Hyman DM, Eaton AA, Gounder MM, Ivy SP, Iasonos A, Spriggs DR. Reply to M. Voskoboynik et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3199-200. PMID 25071117 DOI: 10.1200/JCO.2014.56.5762 |
0.01 |
|
| 2014 |
Rakotz MK, Ewigman BG, Sarav M, Ross RE, Robicsek A, Konchak CW, Gavagan TF, Baker DW, Hyman DJ, Anderson KP, Masi CM. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Annals of Family Medicine. 12: 352-8. PMID 25024244 DOI: 10.1370/Afm.1665 |
0.01 |
|
| 2014 |
Hyman DA, Sage WM. We have strict statutes and most biting laws--reply. Jama Internal Medicine. 174: 1203. PMID 25003894 DOI: 10.1001/jamainternmed.2014.765 |
0.01 |
|
| 2014 |
Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 24: 1010-4. PMID 24978709 DOI: 10.1097/IGC.0000000000000190 |
0.01 |
|
| 2014 |
Grisham RN, Hyman DM, Iyer G. Targeted therapies for treatment of recurrent ovarian cancer. Clinical Advances in Hematology & Oncology : H&O. 12: 158-62. PMID 24927263 |
0.01 |
|
| 2014 |
Beylergil V, Carrasquillo JA, Hyman DM, Diamond EL. Visualization of orbital involvement of Erdheim-Chester disease on PET/CT. Clinical Nuclear Medicine. 39: 660-1. PMID 24873784 DOI: 10.1097/RLU.0000000000000452 |
0.01 |
|
| 2014 |
Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 124: 483-92. PMID 24850756 DOI: 10.1182/blood-2014-03-561381 |
0.01 |
|
| 2014 |
Hyman DM, Grisham RN, Hensley ML. Management of advanced uterine leiomyosarcoma. Current Opinion in Oncology. 26: 422-7. PMID 24840518 DOI: 10.1097/CCO.0000000000000094 |
0.01 |
|
| 2014 |
Sage WM, Hyman DA. Malpractice reform: the authors reply. Health Affairs (Project Hope). 33: 519. PMID 24590955 DOI: 10.1377/hlthaff.2014.0077 |
0.01 |
|
| 2014 |
Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation. Clinical Lymphoma, Myeloma & Leukemia. 14: e65-8. PMID 24445188 DOI: 10.1016/j.clml.2013.12.003 |
0.01 |
|
| 2014 |
Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, Spriggs DR, Ivy P, Iasonos A. Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 519-26. PMID 24419130 DOI: 10.1200/JCO.2013.49.8808 |
0.01 |
|
| 2014 |
Sage WM, Hyman DA. Let's make a deal: trading malpractice reform for health reform. Health Affairs (Project Hope). 33: 53-8. PMID 24395935 DOI: 10.1377/hlthaff.2013.0006 |
0.01 |
|
| 2014 |
McGuckin M, Govednik J, Hyman D, Black B. Public reporting of health care-associated infection rates: are consumers aware and engaged? American Journal of Medical Quality : the Official Journal of the American College of Medical Quality. 29: 83-5. PMID 23880774 DOI: 10.1177/1062860613495441 |
0.01 |
|
| 2014 |
Damberg CL, Hyman D, France J. Do public reports of provider performance make their data and methods available and accessible? Medical Care Research and Review : McRr. 71: 81S-96S. PMID 23838150 DOI: 10.1177/1077558713493670 |
0.01 |
|
| 2014 |
Tabernero J, Chan E, Baselga J, Blay J, Chau I, Hyman DM, Raje NS, Wolf J, Sirzen F, Veronese ML, Mitchell L, Hidalgo M. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). Journal of Clinical Oncology. 32: 3518-3518. DOI: 10.1200/JCO.2014.32.15_SUPPL.3518 |
0.01 |
|
| 2014 |
Hyman DM, Rizvi NA, Natale RB, Armstrong DK, Birrer MJ, Recht LD, Dotan E, Gribbin MJ, McDevitt JT, Tavakkoli F, McCaffrey J, Sikorski R, Lai DW. A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors. Journal of Clinical Oncology. 32: 3012-3012. DOI: 10.1200/Jco.2014.32.15_Suppl.3012 |
0.01 |
|
| 2014 |
Tawbi HA, Chu E, Lin Y, Hyman DM, Goel S, Rudek MA, Dowlati A, LoRusso P, Mulkerin D, Chew HK, Kiesel B, Pollice L, Appleman LJ, Puhalla S, Stoller RG, et al. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). Journal of Clinical Oncology. 32: 2572-2572. DOI: 10.1200/Jco.2014.32.15_Suppl.2572 |
0.01 |
|
| 2014 |
Hyman DM, Blay J, Chau I, Raje NS, Fernandez MEE, Wolf J, Sirzen F, Veronese ML, Mitchell L, Puzanov I, Baselga J. VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). Journal of Clinical Oncology. 32: 2533-2533. DOI: 10.1200/JCO.2014.32.15_SUPPL.2533 |
0.01 |
|
| 2014 |
Abdel-Wahab OI, Diamond EL, Patel M, Holley VR, Cabrilo G, Rampal R, Hassaine L, Kosco K, Baselga J, Kurzrock R, Poole J, Vibat CRT, Erlander M, Janku F, Hyman DM. Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients. Journal of Clinical Oncology. 32: 11012-11012. DOI: 10.1200/Jco.2014.32.15_Suppl.11012 |
0.01 |
|
| 2014 |
Hyman DM, Diamond E, Subbiah V, Blay J, Lockhart AC, Abdel-Wahab O, Sirzen F, Veronese ML, Laserre SF, Elez E, Baselga J. The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study Blood. 124: 635-635. DOI: 10.1182/BLOOD.V124.21.635.635 |
0.01 |
|
| 2014 |
Durham B, Ma J, Kim E, Choi JK, Campbell P, Estrada-Veras J, Walsh MP, Lacouture ME, Chung YR, Nakitandwe J, Diamond E, Hyman DM, Rampal RK, Patel M, Park CY, et al. Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing Blood. 124: 1887-1887. DOI: 10.1182/Blood.V124.21.1887.1887 |
0.01 |
|
| 2014 |
Charen AS, Hyman D, Katabi N, Voss M, Gounder M, Monson K, Stasi M, Winkelman J, Gerecitano J, Carvajal R, Fury M. Parallel Phase I Studies of Two Schedules of Bkm120 Plus Carboplatin and Paclitaxel for Patients with Advanced Solid Tumors Annals of Oncology. 25: iv156. DOI: 10.1093/annonc/mdu331.29 |
0.01 |
|
| 2014 |
Mueller J, Han C, Santos K, Wethington S, Dejbakhsh S, Barakat R, Gardner G, Hyman D, Soslow R, Leitao M. Incidence of lymph node metastasis in comprehensively staged clear cell carcinoma grossly confined to the ovary Gynecologic Oncology. 133: 88. DOI: 10.1016/J.YGYNO.2014.03.235 |
0.01 |
|
| 2014 |
Hyman DA. Why did law professors misunderestimate the lawsuits against ppaca University of Illinois Law Review. 2014: 805-838. |
0.01 |
|
| 2014 |
Hyman DA. Constitutional prognostication: Does anybody knows anything? University of Illinois Law Review. 2014: 1279-1292. |
0.01 |
|
| 2014 |
Hyman DA, Franklyn DJ. Trademarks as search-engine keywords: Who, what, when? Texas Law Review. 92: 2117-2150. |
0.01 |
|
| 2013 |
Hyman DA, Cohen PR. Stasis dermatitis as a complication of recurrent levofloxacin-associated bilateral leg edema. Dermatology Online Journal. 19: 20399. PMID 24314775 |
0.01 |
|
| 2013 |
McGuckin M, Govednik J, Hyman D, Black B. Public reporting of healthcare-associated infections: epidemiologists' perspectives. Infection Control and Hospital Epidemiology. 34: 1201-3. PMID 24113605 DOI: 10.1086/673458 |
0.01 |
|
| 2013 |
Hyman DA, Sage WM. Medical malpractice in the outpatient setting: through a glass, darkly. Jama Internal Medicine. 173: 2069-70. PMID 24081110 DOI: 10.1001/jamainternmed.2013.9193 |
0.01 |
|
| 2013 |
Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, Hyman DM, Rosenblum M. Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 122: 1089-91. PMID 23929840 DOI: 10.1182/blood-2013-02-482984 |
0.01 |
|
| 2013 |
Grigoryan L, Pavlik VN, Hyman DJ. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. Journal of the American Society of Hypertension : Jash. 7: 471-6. PMID 23890931 DOI: 10.1016/j.jash.2013.06.004 |
0.01 |
|
| 2013 |
Kemper C, Blackburn C, Doyle JA, Hyman D. Engaging patients and families in system-level improvement: a safety imperative. Nursing Administration Quarterly. 37: 203-15. PMID 23744466 DOI: 10.1097/Naq.0B013E318295F61E |
0.01 |
|
| 2013 |
Hyman DA, Silver C. Response. Chest. 143: 1835-6. PMID 23732603 DOI: 10.1378/chest.13-0473 |
0.01 |
|
| 2013 |
Amini A, Birnbaum DW, Black B, Hyman DA. Public reporting of hospital infection rates: ranking the states on credibility and user friendliness. Studies in Health Technology and Informatics. 183: 87-92. PMID 23388261 DOI: 10.3233/978-1-61499-203-5-87 |
0.01 |
|
| 2013 |
Grigoryan L, Pavlik VN, Hyman DJ. Patterns of nonadherence to antihypertensive therapy in primary care. Journal of Clinical Hypertension (Greenwich, Conn.). 15: 107-11. PMID 23339728 DOI: 10.1111/jch.12030 |
0.01 |
|
| 2013 |
Hyman DA, Silver C. Five myths of medical malpractice. Chest. 143: 222-7. PMID 23276845 DOI: 10.1378/chest.12-1916 |
0.01 |
|
| 2013 |
Hyman DM, Bakios L, Gualtiere G, Carr C, Grisham RN, Makker V, Sonoda Y, Aghajanian C, Jewell EL. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. Gynecologic Oncology. 129: 58-62. PMID 23274560 DOI: 10.1016/j.ygyno.2012.12.029 |
0.01 |
|
| 2013 |
Hyman DA. Something went wrong on the way to the courthouse. Journal of Health Politics, Policy and Law. 38: 243-53. PMID 23262776 DOI: 10.1215/03616878-1966234 |
0.01 |
|
| 2013 |
Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 119: 548-54. PMID 22930283 DOI: 10.1002/cncr.27782 |
0.01 |
|
| 2013 |
Mansyur CL, Pavlik VN, Hyman DJ, Taylor WC, Goodrick GK. Self-efficacy and barriers to multiple behavior change in low-income African Americans with hypertension. Journal of Behavioral Medicine. 36: 75-85. PMID 22322910 DOI: 10.1007/S10865-012-9403-7 |
0.01 |
|
| 2013 |
Diamond EL, Pentsova E, Borsu L, Chiu AE, Hyman DM, Rosenblum M. Detection of the NRAS Q61R mutation in Erdheim-Chester disease. Journal of Clinical Oncology. 31: 7120-7120. DOI: 10.1200/jco.2013.31.15_suppl.7120 |
0.01 |
|
| 2013 |
Grisham RN, Sala E, Zhou Q, Iasonos A, DeLair D, Iyer G, Hyman DM, Spriggs DR, Aghajanian C. Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Journal of Clinical Oncology. 31: 5545-5545. DOI: 10.1200/JCO.2013.31.15_SUPPL.5545 |
0.01 |
|
| 2013 |
Gerecitano JF, Schwartz GK, Carvajal R, Fury M, Konner J, Hyman DM, Gounder M, Gajria D, Teitcher J, Zhang Z, Moskowitz CH, Beumer JH, Chen A, Little RF, France F, et al. ABT-888 Plus Bendamustine Is Safe and Has Shown Preliminary Efficacy In Patients With Lymphoma Blood. 122: 4366-4366. DOI: 10.1182/BLOOD.V122.21.4366.4366 |
0.01 |
|
| 2013 |
Paik M, Black B, Hyman D. The Receding Tide of Medical Malpractice Litigation: Part 2-Effect of Damage Caps Journal of Empirical Legal Studies. 10: 639-669. DOI: 10.1111/jels.12022 |
0.01 |
|
| 2013 |
Hyman D. Testimony of David Hyman, General Counsel, Netflix. Inc, hearing on "the future of video", Online Video Distributors: An Exploration of Legal and Regulatory Issues. 57-59. |
0.01 |
|
| 2013 |
Hyman DA, Kovacic WE. Institutional design, agency life cycle, and the goals of competition law Fordham Law Review. 81: 2163-2174. |
0.01 |
|
| 2012 |
Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, O'Quigley J. The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5179-87. PMID 22825582 DOI: 10.1158/1078-0432.Ccr-12-0726 |
0.01 |
|
| 2012 |
Hyman D, Laire M, Redmond D, Kaplan DW. The use of patient pictures and verification screens to reduce computerized provider order entry errors Pediatrics. 130. PMID 22665415 DOI: 10.1542/peds.2011-2984 |
0.01 |
|
| 2012 |
Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 807-11. PMID 22635030 DOI: 10.1097/IGC.0b013e31824a33a2 |
0.01 |
|
| 2012 |
Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecologic Oncology. 126: 224-8. PMID 22579790 DOI: 10.1016/j.ygyno.2012.05.001 |
0.01 |
|
| 2012 |
Hyman D, Morales-Vidal S, Schneck MJ. Antithrombotic therapy for stroke prevention in patients with heart failure. Current Treatment Options in Cardiovascular Medicine. 14: 215-26. PMID 22451325 DOI: 10.1007/s11936-012-0177-6 |
0.01 |
|
| 2012 |
Grigoryan L, Pavlik VN, Hyman DJ. Predictors of antihypertensive medication adherence in two urban health-care systems. American Journal of Hypertension. 25: 735-8. PMID 22441507 DOI: 10.1038/ajh.2012.30 |
0.01 |
|
| 2012 |
Hyman DM, Spriggs DR. Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. Jama. 307: 408-10. PMID 22274690 DOI: 10.1001/jama.2012.24 |
0.01 |
|
| 2012 |
Cheung LK, Agi R, Hyman DJ. Warfarin resistance associated with parenteral nutrition. The American Journal of the Medical Sciences. 343: 255-8. PMID 22143126 DOI: 10.1097/MAJ.0b013e3182382553 |
0.01 |
|
| 2012 |
Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 118: 3703-9. PMID 22139894 DOI: 10.1002/cncr.26655 |
0.01 |
|
| 2012 |
Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Miranov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Investigational New Drugs. 30: 2294-302. PMID 22072399 DOI: 10.1007/s10637-011-9765-7 |
0.01 |
|
| 2012 |
Hyman DJ, Pavlik VN, Greisinger AJ, Chan W, Bayona J, Mansyur C, Simms V, Pool J. Effect of a physician uncertainty reduction intervention on blood pressure in uncontrolled hypertensives--a cluster randomized trial. Journal of General Internal Medicine. 27: 413-9. PMID 22033742 DOI: 10.1007/S11606-011-1888-1 |
0.01 |
|
| 2012 |
Hyman DM, Garg K, Grisham RN, Bhatia J, Arnold AG, Aghajanian C, Kauff ND, Levine DA, Soslow RA, Spriggs DR. BRCA1 immunohistochemistry in high-grade serous ovarian cancers (HGS-OC) characterized for BRCA1 germ-line mutations. Journal of Clinical Oncology. 30: 5043-5043. DOI: 10.1200/JCO.2012.30.15_SUPPL.5043 |
0.01 |
|
| 2012 |
Grisham RN, Garg K, Zhou Q, Iasonos A, Berger MF, Dao F, Hyman DM, Levine DA, Solit DB, Aghajanian C, Iyer G. A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC). Journal of Clinical Oncology. 30: 5030-5030. DOI: 10.1200/JCO.2012.30.15_SUPPL.5030 |
0.01 |
|
| 2012 |
Hyman DA, Silver C. Justice Has (Almost) Nothing to Do With It: Medical Malpractice and Tort Reform Medicine and Social Justice: Essays On the Distribution of Health Care. DOI: 10.1093/acprof:osobl/9780199744206.003.0043 |
0.01 |
|
| 2012 |
Hyman DJ, Vallbona C, Pavlik VN. Hypertension in Hispanics Hypertension: a Companion to Braunwald's Heart Disease: Second Edition. 365-368. DOI: 10.1016/B978-1-4377-2766-1.00041-7 |
0.01 |
|
| 2011 |
Hyman DM, Zhou Q, Arnold AG, Grisham RN, Bhatia J, Aghajanian C, Iasonos A, Spriggs DR, Kauff ND. Topoisomerase I inhibition in BRCA+ and BRCA- ovarian cancer (OC): A single-institution experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15557. PMID 28023713 DOI: 10.1200/jco.2011.29.15_suppl.e15557 |
0.01 |
|
| 2011 |
Grisham RN, Adaniel CH, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner JA. Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5098. PMID 28023639 DOI: 10.1200/jco.2011.29.15_suppl.5098 |
0.01 |
|
| 2011 |
Hyman DM, Soff GA, Kampel LJ. Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology. 81: 119-25. PMID 21986538 DOI: 10.1159/000331705 |
0.01 |
|
| 2011 |
Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology. 123: 196-9. PMID 21855118 DOI: 10.1016/j.ygyno.2011.07.019 |
0.01 |
|
| 2011 |
Hyman DA, Black B, Silver C. Settlement at Policy Limits and the Duty to Settle: Evidence from Texas Journal of Empirical Legal Studies. 8: 48-84. DOI: 10.1111/j.1740-1461.2010.01207.x |
0.01 |
|
| 2011 |
Hyman DA. Convicts and convictions: Some lessons from transportation for health reform University of Pennsylvania Law Review. 159: 1999-2042. |
0.01 |
|
| 2010 |
Bedi G, Hyman D, de Wit H. Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biological Psychiatry. 68: 1134-40. PMID 20947066 DOI: 10.1016/J.Biopsych.2010.08.003 |
0.01 |
|
| 2010 |
Hyman DA. Follow the money: money matters in health care, just like in everything else. American Journal of Law & Medicine. 36: 370-88. PMID 20726401 |
0.01 |
|
| 2010 |
Scarlata CJ, Hyman DA. Development and validation of a fast high pressure liquid chromatography method for the analysis of lignocellulosic biomass hydrolysis and fermentation products Journal of Chromatography A. 1217: 2082-2087. PMID 20202640 DOI: 10.1016/j.chroma.2010.01.061 |
0.01 |
|
| 2010 |
Khan R, Hyman D. Hematochezia in the young patient: a review of health-seeking behavior, physician attitudes, and controversies in management. Digestive Diseases and Sciences. 55: 233-9. PMID 19238544 DOI: 10.1007/s10620-009-0750-3 |
0.01 |
|
| 2010 |
Hyman DM, Scher HI, Kampel LJ. Prostate cancer with disseminated intravascular coagulation and excessive fibrinolysis (DIC XFL). Journal of Clinical Oncology. 28: e15063-e15063. DOI: 10.1200/jco.2010.28.15_suppl.e15063 |
0.01 |
|
| 2010 |
Hyman DA. Health Care Fragmentation The Fragmentation of U.S. Health Care: Causes and Solutions. DOI: 10.1093/acprof:oso/9780195390131.003.002 |
0.01 |
|
| 2010 |
Park TH, Hyman D, Leonard P, Wu W. Systematic and Quantative Electro-acoustic Music Analysis (SQEMA) International Computer Music Conference, Icmc 2010. 199-206. |
0.01 |
|
| 2009 |
Pavlik VN, Greisinger AJ, Pool J, Haidet P, Hyman DJ. Does reducing physician uncertainty improve hypertension control?: rationale and methods. Circulation. Cardiovascular Quality and Outcomes. 2: 257-63. PMID 20031846 DOI: 10.1161/CIRCOUTCOMES.109.849984 |
0.01 |
|
| 2009 |
Hyman DJ, Taffet GE. Blood pressure control in the elderly: can you have too much of a good thing? Current Hypertension Reports. 11: 337-42. PMID 19737450 DOI: 10.1007/s11906-009-0057-y |
0.01 |
|
| 2009 |
Hyman DA. Employment-based health insurance and universal coverage: four things people know that aren't so. Yale Journal of Health Policy, Law, and Ethics. 9: 435-52. PMID 19725389 |
0.01 |
|
| 2009 |
Neuspiel DR, Hyman D, Lane M. Quality Improvement and Patient Safety in the Pediatric Ambulatory Setting: Current Knowledge and Implications for Residency Training Pediatric Clinics of North America. 56: 935-951. PMID 19660636 DOI: 10.1016/j.pcl.2009.05.011 |
0.01 |
|
| 2009 |
Hyman DA. Health insurance Labor and Employment Law and Economics. 172-182. |
0.01 |
|
| 2009 |
Abramson E, Hyman D, Osorio N, Kaushal R. Implementing a patient safety and quality program across two merged pediatric institutions Joint Commission Journal On Quality and Patient Safety. 35: 43-48. |
0.01 |
|
| 2008 |
Volk RJ, Jibaja-Weiss ML, Hawley ST, Kneuper S, Spann SJ, Miles BJ, Hyman DJ. Entertainment education for prostate cancer screening: a randomized trial among primary care patients with low health literacy. Patient Education and Counseling. 73: 482-9. PMID 18760888 DOI: 10.1016/j.pec.2008.07.033 |
0.01 |
|
| 2008 |
Ghodsian B, Bogdanoff P, Hyman D. Wideband DC-contact MEMS series switch Micro and Nano Letters. 3: 63-69. DOI: 10.1049/mnl:20080009 |
0.01 |
|
| 2008 |
Hyman DA. On my mind Forbes. 182: 34. |
0.01 |
|
| 2008 |
Hyman DJ. RF MEMS hybrid package testing International Conference and Exhibition On Device Packaging 2009. 3: 1375-1404. |
0.01 |
|
| 2007 |
Lin G, Spann S, Hyman D, Pavlik V. Climate amenity and BMI. Obesity (Silver Spring, Md.). 15: 2120-7. PMID 17712131 DOI: 10.1038/oby.2007.252 |
0.01 |
|
| 2007 |
Hyman DJ, Pavlik VN, Taylor WC, Goodrick GK, Moye L. Simultaneous vs sequential counseling for multiple behavior change. Archives of Internal Medicine. 167: 1152-8. PMID 17563023 DOI: 10.1001/Archinte.167.11.1152 |
0.01 |
|
| 2007 |
Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. The American Journal of Medicine. 120: 194-202. PMID 17349437 DOI: 10.1016/j.amjmed.2006.11.020 |
0.01 |
|
| 2007 |
Hyman DA. Institutional review boards: Is this the least worst we can do? Northwestern University Law Review. 101: 749-773. |
0.01 |
|
| 2006 |
Gavagan TF, Smart K, Palacio H, Dyer C, Greenberg S, Sirbaugh P, Fishkind A, Hamilton D, Shah U, Masi G, Ivey RT, Jones J, Chiou-Tan FY, Bloodworth D, Hyman D, et al. Hurricane Katrina: medical response at the Houston Astrodome/Reliant Center Complex. Southern Medical Journal. 99: 933-9. PMID 17004527 DOI: 10.1097/00007611-200609000-00012 |
0.01 |
|
| 2006 |
Hyman DA, Sage WM. Subsidizing health care providers through the tax code: status or conduct? Health Affairs (Project Hope). 25: W312-5. PMID 16787934 DOI: 10.1377/hlthaff.25.w312 |
0.01 |
|
| 2006 |
Hyman DA, Jacobson P. Is a dose of competition just what the doctor ordered? Journal of Health Politics, Policy and Law. 31: 423-35. PMID 16785291 DOI: 10.1215/03616878-2005-001 |
0.01 |
|
| 2006 |
Hyman DA. The social context of competition policy: Endnote Journal of Health Politics, Policy and Law. 31: 705-706. DOI: 10.1215/03616878-2005-015 |
0.01 |
|
| 2006 |
Hyman DA. Rescue without law: An empirical perspective on the duty to rescue Texas Law Review. 84: 653-737. |
0.01 |
|
| 2006 |
Hyman DA. Getting the haves to come out behind: Fixing the distributive injustices of American health caare Law and Contemporary Problems. 69: 265-282. |
0.01 |
|
| 2006 |
Hyman DA, Silver C. Medical malpractice litigation and tort reform: It's the incentives, stupid Vanderbilt Law Review. 59: 1085-1136. |
0.01 |
|
| 2006 |
Hyman DJ, Kuroda R. Flip-chip assembly of RF MEMS for microwave hybrid circuitry Proceedings of the Asme/Pacific Rim Technical Conference and Exhibition On Integration and Packaging of Mems, Nems, and Electronic Systems: Advances in Electronic Packaging 2005. 2053-2056. |
0.01 |
|
| 2005 |
Bitondo Dyer C, Toronjo C, Cunningham M, Festa NA, Pavlik VN, Hyman DJ, Poythress EL, Searle NS. The key elements of elder neglect:a survey of adult protective service workers. Journal of Elder Abuse & Neglect. 17: 1-10. PMID 17050489 |
0.01 |
|
| 2005 |
Hyman DA, Silver C. The poor state of health care quality in the U.S.: is malpractice liability part of the problem or part of the solution? Cornell Law Review. 90: 893-993. PMID 15954245 |
0.01 |
|
| 2005 |
Lin SX, Hyman D, Larson E. Provision of health counseling in office-based practices and hospital outpatient clinics Preventive Medicine. 40: 542-546. PMID 15749136 DOI: 10.1016/J.Ypmed.2004.06.015 |
0.01 |
|
| 2005 |
Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 24: 42-50. PMID 15459509 DOI: 10.1159/000081049 |
0.01 |
|
| 2005 |
Stevens SH, Schoell M, Ballentine C, Hyman DM. Isotopic analysis of natural CO2 fields: How long has nature stored CO2 underground? Greenhouse Gas Control Technologies. 1375-1379. DOI: 10.1016/B978-008044704-9/50152-X |
0.01 |
|
| 2004 |
Pavlik VN, Hyman DJ, Wendt JA, Orengo C. Association of a culturally defined syndrome (nervios) with chest pain and DSM-IV affective disorders in Hispanic patients referred for cardiac stress testing. Ethnicity & Disease. 14: 505-14. PMID 15724769 |
0.01 |
|
| 2004 |
Hyman DA, Kovacic WE. Monopoly, monopsony, and market definition: an antitrust perspective on market concentration among health insurers. Health Affairs (Project Hope). 23: 25-8. PMID 15537581 DOI: 10.1377/hlthaff.23.6.25 |
0.01 |
|
| 2004 |
Hyman DA. Five reasons why health care quality research hasn't affected competition law and policy. International Journal of Health Care Finance and Economics. 4: 159-66. PMID 15211104 DOI: 10.1023/B:IHFE.0000032421.54279.c6 |
0.01 |
|
| 2004 |
Hyman DA, Silver C. Believing six improbable things: Medical malpractice and "legal fear", Harvard Journal of Law and Public Policy. 28: 107-118. |
0.01 |
|
| 2003 |
Hyman DA. An outsider perspective on intellectual property discourse. Advances in Genetics. 50: 275-86; discussion 5. PMID 14714696 DOI: 10.1016/S0065-2660(03)50014-1 |
0.01 |
|
| 2003 |
Hyman D. Reorganizing health systems to promote best practice medical care, patient self-management, and family-centered care for childhood asthma Ethnicity and Disease. 13. PMID 14552463 |
0.01 |
|
| 2003 |
Wayne DB, Greenberg SB, Pavlik VN, Helmer DA, Hyman DJ. Ambulatory internal medicine education: use of an urgent care center. Southern Medical Journal. 96: 876-9. PMID 14513983 DOI: 10.1097/01.SMJ.0000054938.43211.7A |
0.01 |
|
| 2003 |
Assadi M, Baseman S, Hyman D. Tc SPECT scan in a patient with occipital lobe infarction and complex visual hallucinations The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses. 35: 175-177. PMID 12830666 |
0.01 |
|
| 2003 |
Pavlik VN, Hyman DJ. How well are we managing and monitoring high blood pressure? Current Opinion in Nephrology and Hypertension. 12: 299-304. PMID 12698069 DOI: 10.1097/01.mnh.0000069864.94246.d0 |
0.01 |
|
| 2003 |
Sage WM, Hyman DA, Greenberg W. Why competition law matters to health care quality. Health Affairs (Project Hope). 22: 31-44. PMID 12674406 DOI: 10.1377/hlthaff.22.2.31 |
0.01 |
|
| 2003 |
Hyman DA. Does medicare care about quality? Perspectives in Biology and Medicine. 46: 55-68. PMID 12582270 |
0.01 |
|
| 2003 |
Pavlik VN, de Moraes SA, Szklo M, Knopman DS, Mosley TH, Hyman DJ. Relation between cognitive function and mortality in middle-aged adults: the atherosclerosis risk in communities study. American Journal of Epidemiology. 157: 327-34. PMID 12578803 DOI: 10.1093/Aje/Kwf209 |
0.01 |
|
| 2003 |
Hyman DJ, Pavlik VN. Uncontrolled hypertension as a risk for coronary artery disease: patient characteristics and the role of physician intervention. Current Atherosclerosis Reports. 5: 131-8. PMID 12573199 |
0.01 |
|
| 2003 |
Hyman DA. Does technology spell trouble with a capital "T"?: Human dignity and public policy Harvard Journal of Law and Public Policy. 27: 3-18. |
0.01 |
|
| 2003 |
Gurgevich EA, Hyman D, Alter TR. Creation of UniSCOPE: A model for rewarding all forms of scholarship Journal of Asynchronous Learning Network. 7. |
0.01 |
|
| 2002 |
Hyman DJ, Pavlik VN. Poor hypertension control: let's stop blaming the patients. Cleveland Clinic Journal of Medicine. 69: 793-9. PMID 12371802 |
0.01 |
|
| 2002 |
Hyman DJ, Henry A, Taylor A. Severe rhabdomyolysis related to cerivastatin without gemfibrozil. Annals of Internal Medicine. 137: 74. PMID 12093260 |
0.01 |
|
| 2002 |
Harrell R, Toronjo CH, McLaughlin J, Pavlik VN, Hyman DJ, Dyer CB. How geriatricians identify elder abuse and neglect. The American Journal of the Medical Sciences. 323: 34-8. PMID 11814140 |
0.01 |
|
| 2002 |
Hyman DA. HIPAA and health care fraud: An empirical perspective Cato Journal. 22: 151-178. |
0.01 |
|
| 2002 |
Patel MP, Reshotko E, Hyman D. Microfabricated shear-stress sensors, Part 3: Reducing calibration uncertainty Aiaa Journal. 40: 1582-1588. |
0.01 |
|
| 2001 |
Hyman DA, Hall M. Two cheers for employment-based health insurance Yale Journal of Health Policy, Law, and Ethics. 2: 23-57. PMID 12664936 |
0.01 |
|
| 2001 |
Hyman DA. Health care fraud and abuse: Market change, social norms, and the trust "reposed in the workmen", Journal of Legal Studies. 30: 531. PMID 12647746 |
0.01 |
|
| 2001 |
Wayne DB, Trajtenberg CP, Hyman DJ. Tooth and periodontal disease: a review for the primary-care physician. Southern Medical Journal. 94: 925-32. PMID 11592756 |
0.01 |
|
| 2001 |
Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. The New England Journal of Medicine. 345: 479-86. PMID 11519501 DOI: 10.1056/NEJMoa010273 |
0.01 |
|
| 2001 |
Hyman DA, Silver C. Just what the patient ordered: The case for result-based compensation arrangements Journal of Law, Medicine and Ethics. 29: 170-173. PMID 11508193 |
0.01 |
|
| 2001 |
Vasandani G, Hyman DJ, Pavlik V. Other factors in self-reported hypertension treatment practices among primary care physicians [1] (multiple letters) Archives of Internal Medicine. 161: 1458. PMID 11386898 |
0.01 |
|
| 2001 |
Hyman DA. What lessons should we learn from drive-through deliveries? Pediatrics. 107: 406-408. PMID 11158476 DOI: 10.1542/peds.107.2.406 |
0.01 |
|
| 2001 |
Hyman D, Bridger J, Shingler J, Van Loon M. Paradigms, policies, and people: Exploring the linkages between normative beliefs, public policies and utility consumer payment problems Policy Studies Review. 18: 89-121. |
0.01 |
|
| 2000 |
Hyman DA. Regulating managed care: What's wrong with a patient bill of rights Southern California Law Review. 73: 221. PMID 12731503 |
0.01 |
|
| 2000 |
Hyman DJ, Pavlik VN, Vallbona C. Physician Role in Lack of Awareness and Control of Hypertension. Journal of Clinical Hypertension (Greenwich, Conn.). 2: 324-330. PMID 11416669 |
0.01 |
|
| 2000 |
Pavlik VN, Hyman DJ, Toronjo C. Comparison of Automated and Mercury Column Blood Pressure Measurements in Health Care Settings. Journal of Clinical Hypertension (Greenwich, Conn.). 2: 81-86. PMID 11416630 |
0.01 |
|
| 2000 |
Hyman DA. Do good stories make for good policy? Journal of Health Politics, Policy and Law. 25: 1149-1155. PMID 11142055 |
0.01 |
|
| 2000 |
Hyman DA. Medicine in the new millennium: A self-help guide for the perplexed American Journal of Law and Medicine. 26: 143-154. PMID 10953768 |
0.01 |
|
| 2000 |
Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Archives of Internal Medicine. 160: 2281-6. PMID 10927724 |
0.01 |
|
| 2000 |
Pettignano R, Holloway SE, Hyman D, LaBuz M. Is the Leak Test Reproducible? Southern Medical Journal. 93: 683-685. PMID 10923956 |
0.01 |
|
| 1999 |
Hyman DA. Managed care at the millennium: Scenes from a Maul Journal of Health Politics, Policy and Law. 24: 1061-1070. PMID 10615617 |
0.01 |
|
| 1999 |
Bang CA, Pan T, Hyman DJ. Micromachined heat sinks Sae Technical Papers. DOI: 10.4271/1999-01-1408 |
0.01 |
|
| 1999 |
Hyman D, Pan T, Reshotko E, Mehregany M. Microfabricated shear stress sensors, part 2: Testing and calibration Aiaa Journal. 37: 73-78. DOI: 10.2514/2.666 |
0.01 |
|
| 1999 |
Pan T, Hyman D, Mehregany M, Reshotko E, Garverick S. Microfabricated shear stress sensors, part 1: Design and fabrication Aiaa Journal. 37: 66-72. DOI: 10.2514/2.665 |
0.01 |
|
| 1999 |
Hyman D, Mehregany M. Contact physics of gold microcontacts for MEMS switches Ieee Transactions On Components and Packaging Technologies. 22: 357-364. DOI: 10.1109/6144.796533 |
0.01 |
|
| 1999 |
Hyman D, Shingler J. The hierarchy of consumer participation and patterns of economic, social, and political participation Journal of Consumer Affairs. 33: 380-407. |
0.01 |
|
| 1998 |
Hyman DA, Silver C. IVF shared-risk programs The Journal of Law, Medicine &Amp; Ethics : a Journal of the American Society of Law, Medicine &Amp; Ethics. 26: 79-80. PMID 11067595 |
0.01 |
|
| 1998 |
Hyman DA. Patient dumping and EMTALA: past imperfect/future shock Health Matrix (Cleveland, Ohio : 1991). 8: 29-56. PMID 10179281 |
0.01 |
|
| 1998 |
Frazier S, Hyman D, Altschuler S. The changing health care environment: Implications for residency training Pediatrics. 101: 795-804. PMID 9544185 |
0.01 |
|
| 1998 |
Hyman DA. A second opinion on second opinions Virginia Law Review. 84: 1439. |
0.01 |
|
| 1997 |
Manski RJ, Peddicord D, Hyman D. Medicaid, Managed Care, and America's Health Safety Net Journal of Law, Medicine and Ethics. 25: 30-33. PMID 11066472 |
0.01 |
|
| 1997 |
Hyman DM, Watzlaf GR. METALS AND OTHER COMPONENTS OF COAL MINE DRAINAGE AS RELATED TO AQUATIC LIFE STANDARDS Journal American Society of Mining and Reclamation. 1997: 531-545. DOI: 10.21000/JASMR97010531 |
0.01 |
|
| 1996 |
Hyman DW. The regulation of health claims in food advertising: Have the FTC and the FDA finally reached a common ground? Food and Drug Law Journal. 51: 191-205. PMID 11794351 |
0.01 |
|
| 1996 |
Kiefe CI, Hyman DJ. Do public clinic systems provide health care access for the urban poor? A cross-sectional survey. Journal of Community Health. 21: 61-70. PMID 8903584 DOI: 10.1007/Bf01682764 |
0.01 |
|
| 1996 |
Pavlik VN, Hyman DJ, Vallbona C. Hypertension control in multi-ethnic primary care clinics. Journal of Human Hypertension. 10: S19-23. PMID 8872819 |
0.01 |
|
| 1994 |
Vallbona C, Hyman DJ. Improving health care for the poor. Jama. 272: 352-3; author reply . PMID 8028158 DOI: 10.1001/jama.1994.03520050029015 |
0.01 |
|
| 1992 |
Hyman DJ, Paradis G, Flora JA. A comparison of participants and nonparticipants in a worksite cholesterol screening American Journal of Health Promotion. 7: 137-141. PMID 10148718 |
0.01 |
|
| 1992 |
Hyman DJ, Barrett DC, Fortmann SP. Effect of minor illness on serum cholesterol level. American Journal of Preventive Medicine. 8: 100-3. PMID 1599716 |
0.01 |
|
| 1992 |
Hyman D, Gutman LT. Prophylactic use of trimethoprim-sulfamethoxazole in children with recurrent otitis media Pediatric Infectious Disease Journal. 11: 685. PMID 1523088 |
0.01 |
|
| 1992 |
Hyman DA. Professional profiteering? The ethics of physician entrepreneurship Perspectives in Biology and Medicine. 35: 318-329. PMID 1501995 |
0.01 |
|
| 1992 |
Hyman DM. Discrete analysis in commutative rings Journal of Mathematical Analysis and Applications. 171: 537-554. DOI: 10.1016/0022-247X(92)90364-J |
0.01 |
|
| 1992 |
Hyman DM. A theory of discrete analysis Journal of Mathematical Analysis and Applications. 169: 374-390. DOI: 10.1016/0022-247X(92)90085-R |
0.01 |
|
| 1991 |
Hyman DA. Peer review: current law and policy problems Healthspan. 8: 3-10. PMID 10114029 |
0.01 |
|
| 1991 |
Varela M, Shapira E, Hyman DB. Ullrich-Turner syndrome in mother and daughter: Prenatal diagnosis of a 46,X,del(X)(p21) offspring from a 45,X mother with low-level mosaicism for the del(X)(p21) in one ovary American Journal of Medical Genetics. 39: 411-412. PMID 1877618 |
0.01 |
|
| 1991 |
Hyman D, Wadsworth M, Alexander DP. Values, policy-making, and implementation: The Roots of Bias in Utility Regulatory and Energy Mediation Policy Administration &Amp; Society. 23: 310-332. DOI: 10.1177/009539979102300303 |
0.01 |
|
| 1990 |
Hyman DA. Aesthetics and ethics: The implications of cosmetic surgery Perspectives in Biology and Medicine. 33: 190-202. PMID 2304820 |
0.01 |
|
| 1990 |
Hyman DA. Conflicts of Interest, Continued Jama: the Journal of the American Medical Association. 263: 1199-1200. PMID 2304232 DOI: 10.1001/jama.1990.03440090029015 |
0.01 |
|
| 1990 |
Hyman DA. The conundrum of charitability: Reassessing tax exemption for hospitals American Journal of Law and Medicine. 16: 327-380. PMID 2278243 |
0.01 |
|
| 1990 |
Hyman DA. How law killed ethics Perspectives in Biology and Medicine. 34: 134-151. PMID 2274401 |
0.01 |
|
| 1990 |
Berenson RA, Hyman DA. When opportunity knocks The Hastings Center Report. 20: 33-35; discussion 33. PMID 2135168 |
0.01 |
|
| 1990 |
Hyman DN. Using marginal benefit curves to illustrate income and substitution effects Journal of Economic Education. 21: 383-387. DOI: 10.1080/00220485.1990.10844683 |
0.01 |
|
| Hide low-probability matches. |